alendronate has been researched along with Bone Fractures in 356 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "25OHD = 25-hydroxyvitamin D ALN = alendronate ALP = alkaline phosphatase β-CTX = cross-linked C-telopeptide of type I collagen BMD = bone mineral density BP = bisphosphonate FN = femoral neck LS = lumbar spine OI = osteogenesis imperfecta SAE = severe adverse event ZOL = zoledronic acid." | 9.27 | ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY. ( Jiang, Y; Li, L; Liu, Y; Lv, F; Song, Y; Wang, O; Xia, W; Xing, X; Xu, X, 2018) |
| "The comparative effects of alendronate and alfacalcidol on bone mineral density (BMD) and bone turnover have already been established in postmenopausal women with osteoporosis." | 9.14 | Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M, 2009) |
| "To compare the effects of alendronate and raloxifene on lumbar bone mineral density (BMD), bone turnover, and lipid metabolism in elderly women with osteoporosis." | 9.13 | Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M, 2008) |
| "A 3-year, randomized, double-blind, placebo-controlled trial evaluated the effect of oral alendronate on the BMD of 64 adult patients with osteogenesis imperfecta." | 9.12 | Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. ( Arlot, M; Charrin, JE; Chevrel, G; Duboeuf, F; Fontanges, E; Garnero, P; Lina-Granade, G; Meunier, PJ; Raynal, C; Schott, AM, 2006) |
| "In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more)." | 9.12 | Teriparatide or alendronate in glucocorticoid-induced osteoporosis. ( Boonen, S; Dalsky, GP; Donley, DW; Marcus, R; Marín, F; Saag, KG; Shane, E; Taylor, KA, 2007) |
| "To investigate alendronate for treating osteoporosis in men." | 8.84 | Alendronate for the treatment of osteoporosis in men. ( Davison, KS; Olszynski, WP, 2008) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 8.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| "Efficacy and safety of a new combination package containing 4 or 12 self-explanatory one-week blisters, each with one tablet of 70 mg alendronate (CAS 260055-05-8) and 7 capsules of 1 microg alfacalcidol (CAS 41294-56-8) (Tevabone) on muscle power, muscle function, balance and back pain was investigated in an open, multi-centered, uncontrolled, prospective study on a cohort of elderly patients with a high risk of falls and fractures." | 7.77 | Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective study. ( Ringe, JD; Schacht, E, 2011) |
| "A pre-existing model of osteoporosis was used to predict numbers of fractures, quality-adjusted life-years (QALYs), and costs associated with risedronate or alendronate treatment in post-menopausal (PMO) women aged > or =65 years with a previous vertebral fracture, within the Italian National Health System (NHS)." | 7.76 | Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. ( Berto, P; Lopatriello, S; Maggi, S; Noale, M, 2010) |
| "This population-based study aimed to compare direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate." | 7.75 | Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. ( Blouin, J; Dragomir, A; Fernandes, JC; Fredette, M; Perreault, S; Ste-Marie, LG, 2009) |
| "To evaluate the cost-effectiveness of a fixed dose combination of alendronate 70 mg and cholecalciferol 2800 IU (alendronate/vitamin D3; Fosavance) versus no treatment, alendronate with dietary vitamin D supplements and ibandronate in the treatment of osteoporosis in the UK and Netherlands." | 7.74 | Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands. ( Bergman, G; Gaugris, S; Jansen, JP; Sen, SS, 2008) |
| "A case of osteogenesis imperfecta (OI), which was successfully treated with alendronate is reported." | 7.72 | Effect of treatment with alendronate in osteogenesis imperfecta type I: a case report. ( Iwamoto, J; Sato, Y; Takeda, T, 2004) |
| "Osteoporosis resulting in bone fractures is a complication in patients with primary biliary cirrhosis (PBC)." | 6.78 | Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. ( Cerdá, D; Gifre, L; Guañabens, N; Monegal, A; Muxí, Á; Parés, A; Peris, P, 2013) |
| "Men with osteoporosis have been neglected in the past, and only a few therapeutic trials have been performed in men." | 6.70 | Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. ( Dorst, A; Faber, H; Ringe, JD, 2001) |
| " A subsequent clinical trial reported that the once-weekly dosing regimen is therapeutically equivalent to the daily regimen." | 6.41 | Update on alendronate for osteoporosis: once-weekly dosing. ( Schnitzer, TJ, 2001) |
| "Alendronate has demonstrated its ability to increase bone mass significantly above the placebo values at any studied skeletal site in a wide variety of patient subgroups regardless of age, race, baseline rate of bone turnover or baseline bone mineral density." | 6.40 | A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis. ( Devogelaer, JP, 1998) |
| "Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab, followed by alendronate, reduce clinical fractures in postmenopausal females with osteoporosis." | 5.41 | Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. ( Ayers, C; Fu, R; Harrod, C; Kansagara, D; Kwon, A; Lazur, B, 2023) |
| "Osteoporosis is accompanied by predominantly metaphyseal fractures with a delayed and qualitatively reduced healing process." | 5.36 | Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis? ( Hoerster, AK; Kolios, L; Malcherek, MC; Rack, T; Sehmisch, S; Seidlova-Wuttke, D; Stuermer, EK; Stuermer, KM; Tezval, M; Wuttke, W, 2010) |
| " The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate." | 5.34 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007) |
| "Alendronate was administered to 6-week-old mice during a period of active growth at a dosage of 73 microg alendronate/kg/day for the first 4 weeks and 26 microg alendronate/kg/day for the next 4 weeks." | 5.31 | A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. ( Boskey, AL; Camacho, NP; Doty, SB; Ilg, WA; Raggio, CL; Root, L; Toledano, TR; Zraick, V, 2001) |
| "25OHD = 25-hydroxyvitamin D ALN = alendronate ALP = alkaline phosphatase β-CTX = cross-linked C-telopeptide of type I collagen BMD = bone mineral density BP = bisphosphonate FN = femoral neck LS = lumbar spine OI = osteogenesis imperfecta SAE = severe adverse event ZOL = zoledronic acid." | 5.27 | ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY. ( Jiang, Y; Li, L; Liu, Y; Lv, F; Song, Y; Wang, O; Xia, W; Xing, X; Xu, X, 2018) |
| "The randomized, clinical trial demonstrated that switching to monthly minodronate from weekly alendronate and risedronate provides greater increases in patients' satisfaction and bone mineral density and more substantial decreases in a bone resorption marker than continuing weekly alendronate and risedronate in patients with systemic rheumatic diseases on glucocorticoid therapy." | 5.27 | Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial. ( Hayami, Y; Iwagaitsu, S; Maeda, S; Naniwa, T; Ohmura, SI; Sasaki, K; Tamechika, SY, 2018) |
| "The comparative effects of alendronate and alfacalcidol on bone mineral density (BMD) and bone turnover have already been established in postmenopausal women with osteoporosis." | 5.14 | Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M, 2009) |
| "In an open-label, prospective, controlled, 12-month study the effects of strontium ranelate (SR, CAS 135459-87-9) or alendronate (CAS 129318-43-0) on bone mineral density (BMD) were compared in 152 men with primary osteoporosis." | 5.14 | Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. ( Dorst, A; Farahmand, P; Ringe, JD, 2010) |
| " Subjects had just developed systemic autoimmune diseases and were randomized to be treated with 1 mg/kg/day prednisolone and alfacalcidol 1 microg/day alone (alfacalcidol group; n = 22), or prednisolone and alfacalcidol 1 microg/day with alendronate 5 mg/day (alendronate group; n = 25), each for 18 months." | 5.13 | Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. ( Nakayamada, S; Nawata, M; Okada, Y; Saito, K; Tanaka, Y, 2008) |
| "To compare the effects of alendronate and raloxifene on lumbar bone mineral density (BMD), bone turnover, and lipid metabolism in elderly women with osteoporosis." | 5.13 | Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M, 2008) |
| "A 3-year, randomized, double-blind, placebo-controlled trial evaluated the effect of oral alendronate on the BMD of 64 adult patients with osteogenesis imperfecta." | 5.12 | Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. ( Arlot, M; Charrin, JE; Chevrel, G; Duboeuf, F; Fontanges, E; Garnero, P; Lina-Granade, G; Meunier, PJ; Raynal, C; Schott, AM, 2006) |
| "In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages, 22 to 89 years) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more)." | 5.12 | Teriparatide or alendronate in glucocorticoid-induced osteoporosis. ( Boonen, S; Dalsky, GP; Donley, DW; Marcus, R; Marín, F; Saag, KG; Shane, E; Taylor, KA, 2007) |
| " All patients received vitamin D and calcium supplementation before and after LT, those with osteopenia or osteoporosis prior to LT were additionally treated with alendronate following LT." | 5.11 | Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. ( Eichler, D; Finkenstedt, G; Graziadei, IW; Koenigsrainer, A; Margreiter, R; Millonig, G; Muehllechner, P; Pfeiffer, KP; Vogel, W, 2005) |
| "Alendronate is a second generation bisphosphonate which has been widely used in medical practice for two decades to treat osteoporosis and prevent fragility fractures both in elderly people and in younger patients." | 4.90 | Alendronate: new formulations of an old and effective drug to improve adherence avoiding upper gastrointestinal side effects. ( Auriemma, R; Migliore, A; Neglia, C; Piscitelli, P, 2014) |
| "To investigate alendronate for treating osteoporosis in men." | 4.84 | Alendronate for the treatment of osteoporosis in men. ( Davison, KS; Olszynski, WP, 2008) |
| "For this literature review, published trials of antiresorptive therapy with the bisphosphonates risedronate and alendronate, the selective estrogen receptor modulator raloxifene and calcitonin were reviewed; hormone replacement therapy was not included as this modality is not indicated for treatment of osteoporosis." | 4.82 | Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review. ( Martens, MG, 2003) |
| " We studied 1588 patients over the age of 50 yr who were started on cyclic etidronate (1119) or alendronate (469) in the CANDOO (Canadian Database for Osteoporosis and Osteopenia Patients) Study." | 4.82 | What predicts early fracture or bone loss on bisphosphonate therapy? ( Adachi, JD; Brown, JP; Goldsmith, CH; Hanley, DA; Ioannidis, G; Josse, R; Murray, T; Olszynski, WP; Papaioannou, A; Petrie, A; Sawka, AM; Sebaldt, RJ; Tenenhouse, A, 2003) |
| " Four drugs, calcium, calcitonin, estrogen, and alendronate have been approved for marketing by the Food and Drug Administration for the treatment of osteoporosis." | 4.80 | Medical management of osteoporosis. Fracture prevention. ( Brunelli, MP; Einhorn, TA, 1998) |
| " The parent compound, etidronate, was first used in multicentered trials for the treatment of primary osteoporosis and showed some success in increasing bone density and perhaps controlling fracture rates." | 4.79 | Bisphosphonate therapy. ( Licata, AA, 1997) |
| "The study results indicate that women with osteoporosis initiated on gastro-resistant risedronate have a lower risk of fracture than those initiated on immediate release risedronate or alendronate." | 4.31 | Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. ( Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F, 2023) |
| " This retrospective study assessed the comparability of postmenopausal women, treated with osteoporosis medications with various mechanisms of action such as denosumab (receptor activator of nuclear factor κB ligand [RANKL] inhibitor), zoledronic acid (bisphosphonate derivative), or oral bisphosphonates including alendronate." | 4.31 | Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States. ( Arora, T; Balasubramanian, A; Bradbury, BD; Curtis, JR; Kim, M; Lin, TC; O'Kelly, J; Spangler, L; Stad, RK; Zhao, H, 2023) |
| "To evaluate the cost-effectiveness of four anti-osteoporosis medications (denosumab, zoledronate, teriparatide, and alendronate) for postmenopausal osteoporotic women in mainland China, using a stratified treatment strategy recommended by the American Association of Clinical Endocrinologists and the American College of Endocrinology (AACE/ACE)." | 4.31 | Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis. ( Li, YF; Luo, C; Qu, XL; Sheng, ZF; Tian, L; Wang, QY; Xu, LL; Yang, YY; Yue, C, 2023) |
| "Efficacy and safety of a new combination package containing 4 or 12 self-explanatory one-week blisters, each with one tablet of 70 mg alendronate (CAS 260055-05-8) and 7 capsules of 1 microg alfacalcidol (CAS 41294-56-8) (Tevabone) on muscle power, muscle function, balance and back pain was investigated in an open, multi-centered, uncontrolled, prospective study on a cohort of elderly patients with a high risk of falls and fractures." | 3.77 | Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective study. ( Ringe, JD; Schacht, E, 2011) |
| "A pre-existing model of osteoporosis was used to predict numbers of fractures, quality-adjusted life-years (QALYs), and costs associated with risedronate or alendronate treatment in post-menopausal (PMO) women aged > or =65 years with a previous vertebral fracture, within the Italian National Health System (NHS)." | 3.76 | Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. ( Berto, P; Lopatriello, S; Maggi, S; Noale, M, 2010) |
| "This population-based study aimed to compare direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate." | 3.75 | Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. ( Blouin, J; Dragomir, A; Fernandes, JC; Fredette, M; Perreault, S; Ste-Marie, LG, 2009) |
| " Then 5 rats were confirmed cases of osteoporosis and the remaining 60 were randomly divided into 4 groups 15 each: (1) control group with NS 8 ml x kg(-1) x w(-1); (2) alendronate group with alendronate 40 mg x kg(-1) x w(-1); (3) qianggu group with qianggu capsules 90 mg x kg(-1) x d(-1); (4) co-medicated group with alendronate 40 mg x kg(-1) x w(-1) and qianggu capsules 90 mg x kg(-1) x d(-1)." | 3.75 | [Skeletal biomechanical effectiveness of retinoic acid on induction of osteoporotic rats treated by alendronate and qianggu capsules]. ( Chen, H; Chen, L; Chen, LW; Guo, XS; Qi, DS; Xu, HZ; Zhang, GY, 2009) |
| "5 months of treatment, oral alendronate is associated with a lower fracture rate, improvement in BMD and a decrease in hypercalciuria." | 3.74 | Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective. ( Johari, A; Shah, I, 2007) |
| "To evaluate the cost-effectiveness of a fixed dose combination of alendronate 70 mg and cholecalciferol 2800 IU (alendronate/vitamin D3; Fosavance) versus no treatment, alendronate with dietary vitamin D supplements and ibandronate in the treatment of osteoporosis in the UK and Netherlands." | 3.74 | Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands. ( Bergman, G; Gaugris, S; Jansen, JP; Sen, SS, 2008) |
| "Alendronate, an inhibitor of bone resorption, is widely used in osteoporosis treatment." | 3.73 | Severely suppressed bone turnover: a potential complication of alendronate therapy. ( Gottschalk, FA; Maalouf, N; Odvina, CV; Pak, CY; Rao, DS; Zerwekh, JE, 2005) |
| "To analyse the changes in fracture rate, bone density and histology in children with Osteogenesis imperfecta receiving treatment with alendronate (oral bisphosphonate) and calcitriol." | 3.72 | Treatment of children with Osteogenesis imperfecta in Estonia. ( Haviko, T; Maasalu, K; Märtson, A, 2003) |
| "A case of osteogenesis imperfecta (OI), which was successfully treated with alendronate is reported." | 3.72 | Effect of treatment with alendronate in osteogenesis imperfecta type I: a case report. ( Iwamoto, J; Sato, Y; Takeda, T, 2004) |
| " Incidences of adverse events, asymptomatic decreases in serum calcium, and evolution of kidney function during the studies were similar across all baseline kidney function groups." | 3.11 | Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. ( Adachi, JD; Albergaria, BH; Cheung, AM; Chines, AA; Gielen, E; Langdahl, BL; Miller, PD; Miyauchi, A; Oates, M; Reid, IR; Santiago, NR; Vanderkelen, M; Wang, Z; Yu, Z, 2022) |
| "Osteoporosis is a disorder of bone mineralisation occurring in about one third of adults with cystic fibrosis." | 3.01 | Bisphosphonates for osteoporosis in people with cystic fibrosis. ( Chang, AB; Conwell, LS; Jeffery, TC, 2023) |
| "Osteoporosis is characterized by low bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility." | 3.01 | Treatment for osteoporosis in people with beta-thalassaemia. ( Bhardwaj, A; Sinha, NK; Swe, KMM, 2023) |
| " We calculated the standard mean deviations with 95% confidence intervals (CI) for bone mineral density (BMD) and T scores after 6 and 12 months treatment, pooled odds ratio and 95% CI for fracture risk, and summarized adverse events." | 3.01 | Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis. ( Leng, Y; Xia, Y; Yang, Y; Yu, X, 2023) |
| " Benefits of long-term use of BPs: Large and important trials (Fracture Intervention Trial Long-term Extension and Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly-Pivotal Fracture Trial) with extended use of alendronate (up to 10 years) and zoledronate (up to 6 years) evidenced significant gain of bone mineral density (BMD) and vertebral fracture risk reduction." | 3.01 | Long-term consequences of osteoporosis therapy with bisphosphonates. ( Alves Coelho, MC; Brasil d'Alva, C; Gehrke, B; Madeira, M, 2023) |
| " Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms." | 2.82 | Novel formulations of oral bisphosphonates in the treatment of osteoporosis. ( Al-Daghri, N; Bock, O; Branco, J; Bruyère, O; Casado, E; Cavalier, E; Cooper, C; Cortet, B; de Wit, M; Fuggle, N; Giusti, A; Halbout, P; Harvey, NC; Hiligsmann, M; Kanis, JA; Kaufman, JM; Kurth, A; Maggi, S; Matijevic, R; Minisola, S; Palacios, S; Radermecker, RP; Reginster, JY; Rizzoli, R; Thomasius, F; Tuzun, S; Veronese, N, 2022) |
| "Osteoporosis resulting in bone fractures is a complication in patients with primary biliary cirrhosis (PBC)." | 2.78 | Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. ( Cerdá, D; Gifre, L; Guañabens, N; Monegal, A; Muxí, Á; Parés, A; Peris, P, 2013) |
| " No serious adverse events were observed in either group and safety profiles were similar." | 2.76 | The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in chinese post-menopausal women at risk of osteoporosis. ( Chen, JY; Chen, L; Pan, L; Sheng, ZY; You, L, 2011) |
| "Alendronate was generally well tolerated, with minor adverse events that resolved uneventfully." | 2.76 | Bioavailability and short-term tolerability of alendronate in glucocorticoid-treated children. ( Carpenter, TO; Connor, JD; Denker, AE; Freeman, A; Larson, P; Matthews, CZ; Nakhla, M; Porras, AG; Wagner, JA; Walson, PD; Ward, LM, 2011) |
| "Pamidronate-treated type III/IV and oral bisphosphonate-treated type I patients showed significant increases in total-hip BMD (0." | 2.75 | Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. ( Gillen, C; Nunes, M; Shapiro, JR; Thompson, CB; Wu, Y, 2010) |
| "Androgen-deprivation therapy (ADT) for prostate cancer is associated with bone loss and osteoporotic fractures." | 2.73 | Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. ( Greenspan, SL; Miller, ME; Nelson, JB; Perera, S; Resnick, NM; Trump, DL; Wagner, JM, 2008) |
| "Treatment with alendronate reduced the risk of clinical fractures to a similar degree in those with (OR: 0." | 2.73 | Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. ( Bauer, DC; Cauley, JA; Cummings, SR; Ensrud, KE; Hochberg, M; Ishani, A; Jamal, SA, 2007) |
| "During the second year, the bone resorption marker, serum N-telopeptide, rose by 27% in the calcitriol group (P< or =0." | 2.72 | Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover. ( Addesso, V; Cohen, A; Mancini, D; Maybaum, S; McMahon, DJ; Namerow, P; Shane, E; Staron, RB, 2006) |
| "Alendronate-treated patients sustained less bone loss at the spine than those in the reference group, and both intervention groups sustained less bone loss at the hip than the reference group." | 2.71 | Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. ( Addesso, V; Lo, SH; Mancini, D; Maybaum, S; McMahon, DJ; Namerow, PB; Pardi, S; Shane, E; Staron, RB; Zucker, M, 2004) |
| "Alendronate-treated women with at least a 30% reduction in bone ALP had a lower risk of non-spine (RH = 0." | 2.71 | Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. ( Bauer, DC; Black, DM; Delmas, PD; Ewing, SK; Garnero, P; Hochberg, M; Orloff, J; Ott, S; Thompson, DE, 2004) |
| "In contrast, bisphosphonates reduce bone resorption and increase BMD." | 2.70 | A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. ( Body, JJ; Correa-Rotter, R; Cumming, DC; Dore, RK; Gaich, GA; Hodsman, AB; Kulkarni, PM; Miller, PD; Papaioannou, A; Peretz, A; Scheele, WH, 2002) |
| "The aim of this study was to provide confirmation that once-weekly dosing with 70 mg of alendronate (seven times the daily oral dose) and twice-weekly dosing with 35 mg is equivalent to the 10-mg once-daily regimen and to gain more extensive safety experience with this new dosing regimen." | 2.70 | Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. ( Adami, S; Bone, G; Foldes, AJ; Greenspan, SL; Kaur, A; Levine, MA; Orloff, JJ; Peverly, CA; Rizzoli, R; Roux, C; Santora, AC; Schnitzer, TJ; Uebelhart, B; Watts, NB, 2002) |
| "Men with osteoporosis have been neglected in the past, and only a few therapeutic trials have been performed in men." | 2.70 | Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. ( Dorst, A; Faber, H; Ringe, JD, 2001) |
| "Alendronate use was not associated with a significant increase in upper GI tract events among women at increased risk for these events (those aged > or =75 years with previous upper GI tract disease or using nonsteroidal anti-inflammatory drugs)." | 2.69 | Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. ( Bauer, DC; Black, D; Ensrud, K; Freedholm, D; Hochberg, M; Musliner, T; Nevitt, M; Thompson, D, 2000) |
| "Postmenopausal osteoporosis is a serious health problem, and additional treatments are needed." | 2.68 | Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. ( Bell, NH; Bröll, J; Dequeker, J; Downs, RW; Favus, M; Liberman, UA; Minne, HW; Quan, H; Rodriguez-Portales, J; Weiss, SR, 1995) |
| "Alendronate (ALN) is an aminobisphosphonate employed as an antiresorptive agent in the treatment of osteoporosis." | 2.68 | Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. ( Bone, HG; Downs, RW; Gertz, BJ; Hale, E; Harris, ST; Kimmel, DB; Licata, AA; McClung, MR; Polvino, WJ; Tucci, JR; Weinstein, RS, 1997) |
| "Many drugs for the treatment of osteoporosis have also been associated with increased risks of serious adverse events." | 2.52 | Osteoporosis: the emperor has no clothes. ( Aspenberg, P; Järvinen, TL; Michaëlsson, K; Sievänen, H, 2015) |
| "The preferred treatment for osteoporosis in men is debated, and pairwise meta-analysis cannot obtain hierarchies of these treatments." | 2.52 | Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis. ( Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| "Inhibition of bone resorption is fully reversible following discontinuation." | 2.49 | Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis. ( Josse, R; Khan, A; Ngui, D; Shapiro, M, 2013) |
| "Postmenopausal osteoporosis is a chronic disease requiring treatment that balances long-term fracture efficacy against risk." | 2.48 | Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). ( Cooper, C; Cortet, B; Diaz-Curiel, M; Kanis, JA; Lorenc, RS; Reginster, JY; Rizzoli, R, 2012) |
| "Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue resulting in compromised bone strength and an increased risk of fracture." | 2.44 | Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates. ( Hochberg, MC, 2008) |
| " In order to improve the efficacy of antiresorptive drugs, fewer demands on patients and better adherence were obtained with less frequent dosing schedule." | 2.44 | [Alendronate and vitamin D (Fosavance): persistence, adherence and importance of vitamin D]. ( Grazio, S; Morović-Vergles, J, 2007) |
| " Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis." | 2.43 | Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2005) |
| "Alendronate has been found to reduce the risk of fractures in postmenopausal women as demonstrated in multiple randomized controlled trials enrolling thousands of women." | 2.43 | Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. ( Adachi, JD; Gafni, A; Hanley, DA; Papaioannou, A; Sawka, AM; Thabane, L, 2005) |
| "Oral daily bisphosphonates carry a potential for gastrointestinal (GI) adverse events, which has been partly addressed by introducing once-weekly regimens." | 2.43 | Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. ( Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM, 2006) |
| " RCTs have demonstrated that the incidence of gastrointestinal tract adverse events in postmenopausal osteoporotic women treated with bisphosphonates and placebo are similar, and also the long-term efficacy and safety of alendronate and risedronate." | 2.43 | Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. ( Iwamoto, J; Sato, Y; Takeda, T, 2006) |
| "The main goal of postmenopausal osteoporosis treatment is to reduce the risk of fragility fractures." | 2.43 | [Osteoporosis: Optimizing treatment strategy]. ( Thomas, T, 2006) |
| " In histomorphometry with iliac bone biopsies, mineralization was normal, and trabecular bone turnover markedly decreased in patients receiving long-term dosing with alendronate." | 2.42 | [Clinical trials of alendronate]. ( Okano, T; Teshima, R, 2003) |
| "Osteoporosis is associated with increased risk of fractures at most skeletal sites." | 2.42 | [Treatment of osteoporosis provided from the orthopaedic surgeon's standpoint]. ( Sohen, S, 2003) |
| "Bisphosphonates suppress bone resorption and bone turnover by a mechanism that depends on their structure." | 2.42 | Postmenopausal osteoporosis and alendronate. ( Pérez-López, FR, 2004) |
| "Alendronate has been approved for treatment of osteoporosis in men, and other treatments for men are under evaluation." | 2.41 | Osteoporosis in elderly: prevention and treatment. ( Deal, C; Srivastava, M, 2002) |
| "Alendronate is an agent for the treatment of osteoporosis that has established safety with regards to bone quality since it neither inhibits bone calcification nor influences fracture healing in chronic administration." | 2.41 | [Pharmacological and clinical properties of alendronate sodium hydrate]. ( Komatsu, S; Ohta, T; Tokutake, N, 2002) |
| "Alendronate has the greatest positive effect on BMD and reduces the incidence of vertebral and nonvertebral fractures." | 2.41 | Prevention and treatment of osteoporosis in women with breast cancer. ( Mincey, BA; Moraghan, TJ; Perez, EA, 2000) |
| "The goal of drug treatment of osteoporosis is to prevent fractures." | 2.41 | [Drug treatment for the treatment of primary osteoporosis]. ( Halbekath, J, 2000) |
| " A subsequent clinical trial reported that the once-weekly dosing regimen is therapeutically equivalent to the daily regimen." | 2.41 | Update on alendronate for osteoporosis: once-weekly dosing. ( Schnitzer, TJ, 2001) |
| " In addition, alendronate was shown to have no adverse effects on bone mineralization or microstructure." | 2.40 | Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy. ( Adachi, JD, 1998) |
| "Alendronate has demonstrated its ability to increase bone mass significantly above the placebo values at any studied skeletal site in a wide variety of patient subgroups regardless of age, race, baseline rate of bone turnover or baseline bone mineral density." | 2.40 | A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis. ( Devogelaer, JP, 1998) |
| "Osteoporosis is a common metabolic bone disease that benefits from many newly developed anti-osteoporosis medications (AOMs)." | 1.91 | Eleven years secular trend of the initiation of anti-osteoporosis medications and subsequent fractures in Taiwan: From 2008 to 2018. ( Chan, DC; Chen, HM; Fu, SH; Huang, CF; Hwang, JS; Lin, JW; Wang, CY; Wu, CH; Yang, JJ; Yang, RS; Yang, TH, 2023) |
| "Osteoporosis is common in older adults leading to fragility fractures at enormous individual and economic cost." | 1.72 | Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults. ( Bishop, S; Gittoes, N; Langley, T; Narayanasamy, M; Paskins, Z; Sahota, O, 2022) |
| "Osteoporosis is characterised by trabecular bone loss resulting from increased osteoclast activation and unbalanced coupling between resorption and formation, which induces a thinning of trabeculae and trabecular perforations." | 1.46 | Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties. ( Abel, RL; Atwood, R; Bhattacharya, R; Boughton, OR; Cobb, JP; Goh, EL; Hansen, U; Jin, A; Karunaratne, A; Ma, S; Patel, B; Vo, NT, 2017) |
| "Osteoporosis is a major health threat nowadays." | 1.43 | Use of drugs against osteoporosis in the Baltic countries during 2010-2014. ( Kõks, S; Laius, O; Maasalu, K; Märtson, A, 2016) |
| "Alendronate treatment was discontinued and, while a suitable kidney donor was sought, the patient was treated for 6 months with teriparatide, which significantly reduced the osteomalacia." | 1.42 | Reversible Deterioration in Hypophosphatasia Caused by Renal Failure With Bisphosphonate Treatment. ( Collins, JF; Cundy, T; Dray, M; Fratzl-Zelman, N; Gamsjaeger, S; Klaushofer, K; Michigami, T; Paschalis, EP; Roschger, A; Roschger, P; Tachikawa, K, 2015) |
| "We report a rare association of amniotic bands with osteogenesis imperfecta in a child." | 1.42 | A rare combination of amniotic constriction band with osteogenesis imperfecta. ( Shah, H; Shah, KH, 2015) |
| "Treatment with alendronate (1 μg/kg/day), LIPUS (20 min/day), or a combination of both was administered for 2 or 4 weeks, after which changes in bone mineral density (BMD), bone histomorphometric parameters, and the rate of cancellous bony bonding were measured." | 1.40 | Effects of combined therapy of alendronate and low-intensity pulsed ultrasound on metaphyseal bone repair after osteotomy in the proximal tibia of aged rats. ( Aonuma, H; Kamo, K; Kasukawa, Y; Miyakoshi, N; Sasaki, H; Segawa, T; Shimada, Y; Tsuchie, H, 2014) |
| "Rosiglitazone (RSG) is an antidiabetic drug that has been associated with increased peripheral fractures, primarily in postmenopausal women." | 1.39 | The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate. ( Fitzpatrick, LA; Guldberg, RE; Hoffman, SJ; Jolette, J; Kumar, S; Mansell, P; Samadfam, R; Smith, SY, 2013) |
| " In two trials involving 1189 and 504 women, the incidence of clinical fractures, recorded as simple adverse effects, did not differ significantly between the groups." | 1.37 | Denosumab. Limited efficacy in fracture prevention, too many adverse effects. ( , 2011) |
| " Although existing evidence supports a good safety profile, there is concern that chronic administration of these agents could result in severe suppression of bone turnover with increased risk of nonvertebral fractures." | 1.36 | Unusual mid-shaft fractures during long-term bisphosphonate therapy. ( Levy, S; Odvina, CV; Rao, DS; Rao, S; Zerwekh, JE, 2010) |
| "Osteoporosis is accompanied by predominantly metaphyseal fractures with a delayed and qualitatively reduced healing process." | 1.36 | Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis? ( Hoerster, AK; Kolios, L; Malcherek, MC; Rack, T; Sehmisch, S; Seidlova-Wuttke, D; Stuermer, EK; Stuermer, KM; Tezval, M; Wuttke, W, 2010) |
| "We studied 1515 women with postmenopausal osteoporosis under treatment with anti-resorbing agents (alendronate, risedronate, raloxifene) for 13." | 1.35 | Vitamin D status and response to treatment in post-menopausal osteoporosis. ( Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L, 2009) |
| "Osteoporosis is widely prevalent in India and osteoporotic fractures are a common cause of morbidity and mortality." | 1.35 | Osteoporotic fracture management in India: a survey of orthopaedic surgeons. ( Lakhotia, SM, 2008) |
| "Alendronate is a potent aminobisphosphonate that has been used worldwide to decrease fracture risk in millions of post-menopausal women with and without osteoporosis, men with low bone mass, and in those with glucocorticoid- induced osteoporosis." | 1.35 | Effect of inappropriate and continuous therapy with alendronate for ten years on skeletal integrity - observations in two elderly patients. ( Tucci, JR, 2008) |
| "Alendronate was the reference category in all analyses." | 1.35 | Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. ( Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T, 2008) |
| " The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate." | 1.34 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2007) |
| "For 55 and 60 year old women with osteopenia, treatment with raloxifene compares favorably to interventions accepted as cost-effective." | 1.34 | Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. ( Johnston, JA; Klein, R; Meadows, ES; Ohsfeldt, RL; Rousculp, MD; Smolen, L, 2007) |
| "A history of fracture and a low bone mineral density (BMD) are the strongest predictors of future osteoporotic fracture." | 1.33 | Influence of fracture history and bone mineral density testing on the treatment of osteoporosis in two non-academic community centers. ( Adachi, JD; Goldsmith, CH; Hamel, ME; Papadimitropoulos, E; Petrie, A; Sebaldt, RJ; Siminoski, K, 2005) |
| "Alendronate was assumed to reduce the fracture risk by 50%." | 1.33 | Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. ( Brixen, K; Christensen, PM; Gyrd-Hansen, D; Kristiansen, IS, 2005) |
| "Alendronate has been studied extensively by large trials of high quality and its efficacy to reduce the risk of vertebral and nonvertebral fractures is in line with the criteria of evidence-based medicine." | 1.33 | [Drug therapy for prevention of falls and fractures]. ( Ringe, JD, 2006) |
| "Hadju-Cheney syndrome is characterized by short stature, distinctive facies, and a slowly progressive skeletal dysplasia including acro-osteolysis." | 1.32 | Hadju-Cheney syndrome: response to therapy with bisphosphonates in two patients. ( Drake, WM; Hiorns, MP; Kendler, DL, 2003) |
| "Alendronate was administered to 6-week-old mice during a period of active growth at a dosage of 73 microg alendronate/kg/day for the first 4 weeks and 26 microg alendronate/kg/day for the next 4 weeks." | 1.31 | A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. ( Boskey, AL; Camacho, NP; Doty, SB; Ilg, WA; Raggio, CL; Root, L; Toledano, TR; Zraick, V, 2001) |
| " The drug should be absorbed after an overnight fast to improve its bioavailability and with a big glass of plain water to reduce the risk of oesophageal ulcerations." | 1.30 | [Drug clinics. The drug of the month. Alendronate (Fosamax)]. ( Scheen, AJ, 1998) |
| "Alendronate is a drug with considerable potential." | 1.29 | Alendronate: a new bisphosphonate for the treatment of osteoporosis. ( Keen, RW; Spector, TD, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 45 (12.64) | 18.2507 |
| 2000's | 198 (55.62) | 29.6817 |
| 2010's | 91 (25.56) | 24.3611 |
| 2020's | 22 (6.18) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, PD | 2 |
| Adachi, JD | 6 |
| Albergaria, BH | 1 |
| Cheung, AM | 1 |
| Chines, AA | 1 |
| Gielen, E | 1 |
| Langdahl, BL | 1 |
| Miyauchi, A | 1 |
| Oates, M | 1 |
| Reid, IR | 1 |
| Santiago, NR | 1 |
| Vanderkelen, M | 1 |
| Wang, Z | 1 |
| Yu, Z | 1 |
| Okamoto, M | 1 |
| Kashii, M | 1 |
| Abe, S | 1 |
| McConnell, M | 1 |
| Shieh, A | 1 |
| Fuggle, N | 1 |
| Al-Daghri, N | 1 |
| Bock, O | 1 |
| Branco, J | 1 |
| Bruyère, O | 2 |
| Casado, E | 2 |
| Cavalier, E | 1 |
| Cortet, B | 4 |
| de Wit, M | 1 |
| Giusti, A | 1 |
| Halbout, P | 1 |
| Harvey, NC | 1 |
| Hiligsmann, M | 1 |
| Kaufman, JM | 2 |
| Kurth, A | 1 |
| Maggi, S | 2 |
| Matijevic, R | 1 |
| Minisola, S | 4 |
| Palacios, S | 1 |
| Radermecker, RP | 1 |
| Thomasius, F | 2 |
| Tuzun, S | 1 |
| Veronese, N | 1 |
| Kanis, JA | 3 |
| Reginster, JY | 4 |
| Rizzoli, R | 6 |
| Cooper, C | 4 |
| Narayanasamy, M | 3 |
| Bishop, S | 3 |
| Sahota, O | 3 |
| Paskins, Z | 3 |
| Gittoes, N | 3 |
| Langley, T | 3 |
| Ayers, C | 1 |
| Kansagara, D | 1 |
| Lazur, B | 1 |
| Fu, R | 1 |
| Kwon, A | 1 |
| Harrod, C | 1 |
| Jeffery, TC | 1 |
| Chang, AB | 1 |
| Conwell, LS | 1 |
| Eisman, JA | 1 |
| Boolell, M | 2 |
| Ionescu-Ittu, R | 1 |
| Vekeman, F | 1 |
| Heroux, J | 1 |
| Gharanizadeh, K | 1 |
| Ravanbod, H | 1 |
| Aminian, A | 1 |
| Hatami, S | 1 |
| Chaleshtori, AS | 1 |
| Kazerani, S | 1 |
| Yoon, BK | 1 |
| Kim, M | 1 |
| Lin, TC | 1 |
| Arora, T | 1 |
| Zhao, H | 1 |
| Balasubramanian, A | 1 |
| Stad, RK | 1 |
| O'Kelly, J | 1 |
| Spangler, L | 1 |
| Bradbury, BD | 1 |
| Curtis, JR | 2 |
| Bhardwaj, A | 1 |
| Swe, KMM | 1 |
| Sinha, NK | 1 |
| Yang, TH | 1 |
| Wang, CY | 1 |
| Fu, SH | 1 |
| Chan, DC | 1 |
| Chen, HM | 1 |
| Lin, JW | 1 |
| Huang, CF | 1 |
| Yang, JJ | 1 |
| Wu, CH | 2 |
| Hwang, JS | 1 |
| Yang, RS | 1 |
| Leng, Y | 1 |
| Yu, X | 1 |
| Yang, Y | 1 |
| Xia, Y | 1 |
| Tian, L | 1 |
| Luo, C | 1 |
| Li, YF | 1 |
| Wang, QY | 1 |
| Qu, XL | 1 |
| Yue, C | 1 |
| Xu, LL | 1 |
| Yang, YY | 1 |
| Sheng, ZF | 1 |
| Rosas, J | 1 |
| Rubio-Terrés, C | 1 |
| Rubio-Rodríguez, D | 1 |
| Arístegui, I | 1 |
| Gehrke, B | 1 |
| Alves Coelho, MC | 1 |
| Brasil d'Alva, C | 1 |
| Madeira, M | 1 |
| Uemura, Y | 2 |
| Taguri, M | 1 |
| Kawahara, T | 1 |
| Chiba, Y | 1 |
| Morten, CJ | 1 |
| Kesselheim, AS | 1 |
| Ross, JS | 1 |
| Lau, EMC | 1 |
| Dinavahi, R | 1 |
| Woo, YC | 1 |
| Guan, J | 1 |
| Maddox, J | 2 |
| Tolman, C | 1 |
| Yang, W | 2 |
| Shin, CS | 1 |
| Cosman, F | 4 |
| Lewiecki, EM | 3 |
| Ebeling, PR | 1 |
| Hesse, E | 1 |
| Napoli, N | 2 |
| Matsumoto, T | 1 |
| Crittenden, DB | 1 |
| Rojeski, M | 1 |
| Libanati, C | 1 |
| Ferrari, S | 1 |
| Paik, J | 1 |
| Scott, LJ | 1 |
| Ouyang, Y | 1 |
| Chen, S | 1 |
| Wan, T | 1 |
| Zheng, G | 1 |
| Sun, G | 1 |
| Meunier, A | 1 |
| Palm, L | 1 |
| Aspenberg, P | 2 |
| Schilcher, J | 1 |
| Martín-Merino, E | 1 |
| Huerta-Álvarez, C | 1 |
| Prieto-Alhambra, D | 2 |
| Montero-Corominas, D | 1 |
| Kawada, S | 1 |
| Harada, A | 2 |
| Hashimoto, N | 1 |
| Saag, KG | 4 |
| Petersen, J | 2 |
| Brandi, ML | 1 |
| Karaplis, AC | 1 |
| Lorentzon, M | 2 |
| Thomas, T | 4 |
| Fan, M | 1 |
| Meisner, PD | 1 |
| Grauer, A | 2 |
| Karlsson, L | 1 |
| Mesterton, J | 1 |
| Tepie, MF | 1 |
| Intorcia, M | 1 |
| Overbeek, J | 1 |
| Ström, O | 1 |
| Özer, T | 1 |
| Aktas, A | 1 |
| Barıs, E | 1 |
| Çelik, HH | 1 |
| Vatansever, A | 1 |
| Khosla, S | 1 |
| Al Daghri, N | 1 |
| Lv, F | 3 |
| Guan, Y | 1 |
| Ma, D | 2 |
| Xu, X | 3 |
| Song, Y | 2 |
| Li, L | 2 |
| Jiang, Y | 3 |
| Wang, O | 3 |
| Xia, W | 3 |
| Xing, X | 3 |
| Li, M | 2 |
| Song, GG | 1 |
| Lee, YH | 1 |
| Lewis, JR | 1 |
| Schousboe, JT | 5 |
| Prince, RL | 1 |
| Tsourdi, E | 1 |
| Rachner, TD | 1 |
| Hofbauer, LC | 1 |
| Ferrari, SL | 1 |
| Liu, Y | 2 |
| Wallis, C | 1 |
| Tamechika, SY | 1 |
| Sasaki, K | 1 |
| Hayami, Y | 1 |
| Ohmura, SI | 1 |
| Maeda, S | 1 |
| Iwagaitsu, S | 1 |
| Naniwa, T | 1 |
| Le, QA | 1 |
| Hay, JW | 1 |
| Becker, R | 1 |
| Wang, Y | 1 |
| Nieves, JW | 1 |
| Roimisher, C | 1 |
| Neubort, S | 1 |
| McMahon, DJ | 3 |
| Dempster, DW | 1 |
| Lindsay, R | 5 |
| Duckworth, AD | 1 |
| McQueen, MM | 1 |
| Tuck, CE | 1 |
| Tobias, JH | 1 |
| Wilkinson, JM | 1 |
| Biant, LC | 1 |
| Pulford, EC | 1 |
| Aldridge, S | 1 |
| Edwards, C | 1 |
| Roberts, CP | 1 |
| Ramachandran, M | 1 |
| McAndrew, AR | 1 |
| Cheng, KC | 1 |
| Johnston, P | 1 |
| Shah, NH | 1 |
| Mathew, P | 1 |
| Harvie, J | 1 |
| Hanusch, BC | 1 |
| Harkess, R | 1 |
| Rodriguez, A | 1 |
| Murray, GD | 1 |
| Ralston, SH | 1 |
| Tomecka, MJ | 1 |
| Ethiraj, LP | 1 |
| Sánchez, LM | 1 |
| Roehl, HH | 1 |
| Carney, TJ | 1 |
| Kumar, S | 1 |
| Hoffman, SJ | 1 |
| Samadfam, R | 1 |
| Mansell, P | 1 |
| Jolette, J | 1 |
| Smith, SY | 1 |
| Guldberg, RE | 2 |
| Fitzpatrick, LA | 1 |
| Guañabens, N | 1 |
| Monegal, A | 1 |
| Cerdá, D | 1 |
| Muxí, Á | 1 |
| Gifre, L | 1 |
| Peris, P | 1 |
| Parés, A | 1 |
| Patel, V | 1 |
| Graves, L | 1 |
| Lukert, B | 1 |
| Jiang, Q | 1 |
| Snapinn, S | 1 |
| Aonuma, H | 1 |
| Miyakoshi, N | 1 |
| Kasukawa, Y | 1 |
| Kamo, K | 1 |
| Sasaki, H | 1 |
| Tsuchie, H | 1 |
| Segawa, T | 1 |
| Shimada, Y | 1 |
| Serrano, AJ | 1 |
| Begoña, L | 1 |
| Anitua, E | 1 |
| Cobos, R | 1 |
| Orive, G | 1 |
| Diab, DL | 1 |
| Watts, NB | 6 |
| Tella, SH | 1 |
| Gallagher, JC | 2 |
| van den Bergh, JP | 1 |
| Bouts, ME | 1 |
| van der Veer, E | 1 |
| van der Velde, RY | 1 |
| Janssen, MJ | 1 |
| Geusens, PP | 1 |
| Winkens, B | 1 |
| Oldenhof, NJ | 1 |
| van Geel, TA | 1 |
| McLendon, AN | 1 |
| Woodis, CB | 1 |
| Yano, T | 1 |
| Yamada, M | 1 |
| Konda, T | 1 |
| Shiozaki, M | 1 |
| Inoue, D | 1 |
| Patntirapong, S | 1 |
| Singhatanadgit, W | 1 |
| Arphavasin, S | 1 |
| Gourlay, ML | 1 |
| Ensrud, KE | 13 |
| Bauer, DC | 16 |
| Schwartz, A | 1 |
| Palermo, L | 7 |
| Cauley, J | 2 |
| Hochberg, M | 6 |
| Santora, A | 2 |
| Cummings, SR | 13 |
| Black, DM | 15 |
| Soen, S | 1 |
| Fabiny, A | 1 |
| Watson, HI | 1 |
| Hopper, GP | 1 |
| Gupta, S | 1 |
| Roberts, JL | 1 |
| Burr, DB | 5 |
| Liu, Z | 1 |
| Allen, MR | 4 |
| Piscitelli, P | 1 |
| Auriemma, R | 1 |
| Neglia, C | 1 |
| Migliore, A | 1 |
| Cundy, T | 1 |
| Michigami, T | 1 |
| Tachikawa, K | 1 |
| Dray, M | 1 |
| Collins, JF | 1 |
| Paschalis, EP | 1 |
| Gamsjaeger, S | 1 |
| Roschger, A | 1 |
| Fratzl-Zelman, N | 2 |
| Roschger, P | 3 |
| Klaushofer, K | 3 |
| Järvinen, TL | 1 |
| Michaëlsson, K | 1 |
| Sievänen, H | 1 |
| Boskey, AL | 3 |
| Marino, J | 1 |
| Spevak, L | 1 |
| Pleshko, N | 1 |
| Doty, S | 1 |
| Carter, EM | 1 |
| Raggio, CL | 3 |
| Chen, LX | 1 |
| Zhou, ZR | 1 |
| Li, YL | 1 |
| Ning, GZ | 1 |
| Zhang, TS | 1 |
| Zhang, D | 1 |
| Feng, SQ | 1 |
| Tanaka, Y | 2 |
| Mori, H | 1 |
| Aoki, T | 1 |
| Atsumi, T | 1 |
| Kawahito, Y | 1 |
| Nakayama, H | 1 |
| Tohma, S | 1 |
| Yamanishi, Y | 1 |
| Hasegawa, H | 1 |
| Tanimura, K | 1 |
| Negoro, N | 1 |
| Ueki, Y | 1 |
| Kawakami, A | 1 |
| Eguchi, K | 1 |
| Saito, K | 2 |
| Okada, Y | 2 |
| Gatti, D | 1 |
| Adami, S | 7 |
| Viapiana, O | 1 |
| Rossini, M | 2 |
| Naruse, K | 1 |
| Uchida, K | 1 |
| Suto, M | 1 |
| Miyagawa, K | 1 |
| Kawata, A | 1 |
| Urabe, K | 1 |
| Takaso, M | 1 |
| Itoman, M | 1 |
| Mikuni-Takagaki, Y | 1 |
| Shah, KH | 1 |
| Shah, H | 1 |
| van de Glind, EM | 1 |
| Willems, HC | 1 |
| Eslami, S | 1 |
| Abu-Hanna, A | 1 |
| Lems, WF | 2 |
| Hooft, L | 1 |
| de Rooij, SE | 1 |
| van Munster, BC | 1 |
| Reyes, C | 1 |
| Pottegård, A | 1 |
| Schwarz, P | 1 |
| Javaid, MK | 1 |
| Van Staa, TP | 1 |
| Diez-Perez, A | 1 |
| Abrahamsen, B | 3 |
| Veszelyné Kotán, E | 1 |
| Mészaros, Á | 1 |
| Wang, J | 1 |
| Yu, W | 1 |
| Laius, O | 1 |
| Maasalu, K | 2 |
| Kõks, S | 1 |
| Märtson, A | 2 |
| Ma, S | 1 |
| Goh, EL | 1 |
| Jin, A | 1 |
| Bhattacharya, R | 1 |
| Boughton, OR | 1 |
| Patel, B | 1 |
| Karunaratne, A | 1 |
| Vo, NT | 1 |
| Atwood, R | 1 |
| Cobb, JP | 1 |
| Hansen, U | 1 |
| Abel, RL | 1 |
| Rosen, H | 1 |
| Roerholt, C | 1 |
| Eiken, P | 2 |
| Giannini, S | 1 |
| Bianchi, G | 1 |
| Sinigaglia, L | 3 |
| Di Munno, O | 1 |
| Fiore, CE | 1 |
| Ettinger, B | 2 |
| Hochberg, MC | 6 |
| Tosteson, AN | 1 |
| Burge, RT | 1 |
| Marshall, DA | 1 |
| Brandão, CM | 1 |
| Lima, MG | 1 |
| Silva, AL | 1 |
| Silva, GD | 1 |
| Guerra, AA | 1 |
| Acúrcio, Fde A | 1 |
| Greenspan, SL | 4 |
| Nelson, JB | 1 |
| Trump, DL | 1 |
| Wagner, JM | 1 |
| Miller, ME | 1 |
| Perera, S | 2 |
| Resnick, NM | 1 |
| Okazaki, R | 1 |
| Bonnick, SL | 1 |
| Beck, TJ | 1 |
| Wang, H | 1 |
| de Papp, AE | 2 |
| Lakhotia, SM | 1 |
| Verhaar, HJ | 1 |
| Sheehy, O | 1 |
| Kindundu, CM | 1 |
| Barbeau, M | 1 |
| LeLorier, J | 1 |
| Nawata, M | 1 |
| Nakayamada, S | 1 |
| Blouin, J | 2 |
| Dragomir, A | 2 |
| Fredette, M | 1 |
| Ste-Marie, LG | 2 |
| Fernandes, JC | 2 |
| Perreault, S | 2 |
| Inderjeeth, CA | 1 |
| Foo, AC | 1 |
| Lai, MM | 1 |
| Glendenning, P | 1 |
| Brixen, K | 2 |
| Bize, R | 1 |
| Lamy, O | 1 |
| Peytremann-Bridevaux, I | 1 |
| Ringe, JD | 8 |
| Schacht, E | 3 |
| Mueller, D | 1 |
| Gandjour, A | 1 |
| Geusens, P | 2 |
| Wang, X | 1 |
| Erickson, AM | 1 |
| Martin, RB | 1 |
| Hazelwood, SJ | 1 |
| Odvina, CV | 2 |
| Levy, S | 1 |
| Rao, S | 1 |
| Zerwekh, JE | 2 |
| Rao, DS | 2 |
| Gaál, J | 1 |
| Bender, T | 1 |
| Varga, J | 1 |
| Horváth, I | 1 |
| Kiss, J | 1 |
| Somogyi, P | 1 |
| Surányi, P | 1 |
| Bayly, J | 1 |
| Kuroda, T | 2 |
| Miyakawa, N | 2 |
| Miyazaki, T | 1 |
| Shiraki, M | 4 |
| Ikeda, K | 1 |
| Lombardi, A | 5 |
| Misof, BM | 2 |
| Maier, G | 1 |
| Fratzl, P | 2 |
| Iwamoto, J | 5 |
| Sato, Y | 5 |
| Uzawa, M | 3 |
| Takeda, T | 5 |
| Matsumoto, H | 3 |
| Kolios, L | 1 |
| Hoerster, AK | 1 |
| Sehmisch, S | 1 |
| Malcherek, MC | 1 |
| Rack, T | 1 |
| Tezval, M | 1 |
| Seidlova-Wuttke, D | 1 |
| Wuttke, W | 1 |
| Stuermer, KM | 1 |
| Stuermer, EK | 1 |
| Chen, L | 3 |
| Chen, LW | 1 |
| Chen, H | 1 |
| Guo, XS | 1 |
| Xu, HZ | 1 |
| Zhang, GY | 1 |
| Qi, DS | 1 |
| Berto, P | 1 |
| Noale, M | 1 |
| Lopatriello, S | 1 |
| Schwartz, AV | 6 |
| Cauley, JA | 7 |
| Wallace, RB | 3 |
| Feldstein, AC | 2 |
| Yamazaki, Y | 1 |
| Shiraki, Y | 1 |
| Hosoi, T | 2 |
| Tsugawa, N | 1 |
| Okano, T | 2 |
| O'Neal, JM | 1 |
| Diab, T | 1 |
| Vidakovic, B | 1 |
| Laroche, M | 1 |
| Krieg, MA | 1 |
| Frieling, I | 1 |
| Delmas, P | 2 |
| Felsenberg, D | 2 |
| Dorst, A | 2 |
| Farahmand, P | 1 |
| Shapiro, JR | 1 |
| Thompson, CB | 1 |
| Wu, Y | 1 |
| Nunes, M | 1 |
| Gillen, C | 1 |
| Berry, SD | 1 |
| Misra, D | 1 |
| Hannan, MT | 1 |
| Kiel, DP | 3 |
| Resnick, J | 1 |
| Gupta, N | 1 |
| Wagner, J | 1 |
| Costa, G | 1 |
| Cruz, RJ | 1 |
| Martin, L | 1 |
| Koritsky, DA | 1 |
| Matarese, L | 1 |
| Eid, K | 1 |
| Schuster, B | 1 |
| Roberts, M | 1 |
| Greenspan, S | 1 |
| Abu-Elmagd, K | 1 |
| Delzell, E | 1 |
| Black, D | 6 |
| Ensrud, K | 5 |
| Judd, S | 1 |
| Safford, MM | 1 |
| Ward, LM | 2 |
| Rauch, F | 1 |
| Whyte, MP | 1 |
| D'Astous, J | 1 |
| Gates, PE | 1 |
| Grogan, D | 1 |
| Lester, EL | 1 |
| McCall, RE | 1 |
| Pressly, TA | 1 |
| Sanders, JO | 1 |
| Smith, PA | 1 |
| Steiner, RD | 1 |
| Sullivan, E | 1 |
| Tyerman, G | 1 |
| Smith-Wright, DL | 1 |
| Verbruggen, N | 1 |
| Heyden, N | 1 |
| Glorieux, FH | 1 |
| Alvarez, A | 1 |
| Kremer, R | 1 |
| Weiss, DR | 1 |
| Benedetti, A | 1 |
| Haziza, M | 1 |
| Trojan, DA | 1 |
| Moen, MD | 1 |
| Keam, SJ | 1 |
| Kenealy, H | 1 |
| Paul, S | 1 |
| Walker, K | 1 |
| Garg, A | 1 |
| Dukas, L | 1 |
| Mazor, Z | 1 |
| Vestergaard, P | 1 |
| Mosekilde, L | 1 |
| Langdahl, B | 1 |
| Orimo, H | 1 |
| Nakamura, T | 1 |
| Fukunaga, M | 2 |
| Ohta, H | 1 |
| Ohashi, Y | 1 |
| You, L | 1 |
| Sheng, ZY | 1 |
| Chen, JY | 1 |
| Pan, L | 1 |
| Jayaraman, M | 1 |
| Karikumar, K | 1 |
| Verma, A | 1 |
| Modi, KD | 1 |
| Panico, A | 1 |
| Lupoli, GA | 1 |
| Marciello, F | 1 |
| Lupoli, R | 1 |
| Cacciapuoti, M | 1 |
| Martinelli, A | 1 |
| Granieri, L | 1 |
| Iacono, D | 1 |
| Lupoli, G | 1 |
| Ott, SM | 5 |
| Martin, KE | 1 |
| Yu, J | 1 |
| Campbell, HE | 1 |
| Abarca, J | 1 |
| White, TJ | 1 |
| Nakhla, M | 1 |
| Denker, AE | 1 |
| Connor, JD | 1 |
| Carpenter, TO | 1 |
| Walson, PD | 1 |
| Porras, AG | 1 |
| Matthews, CZ | 1 |
| Larson, P | 1 |
| Freeman, A | 1 |
| Wagner, JA | 1 |
| Diaz-Curiel, M | 2 |
| Lorenc, RS | 1 |
| Eriksen, EF | 1 |
| Halse, J | 1 |
| Marik, IA | 1 |
| Marikova, A | 1 |
| Hudakova, O | 1 |
| Samuels, ME | 1 |
| Kozlowski, KS | 1 |
| Josse, R | 3 |
| Khan, A | 1 |
| Ngui, D | 1 |
| Shapiro, M | 1 |
| Majumdar, SR | 1 |
| Lier, DA | 1 |
| McAlister, FA | 1 |
| Rowe, BH | 1 |
| Siminoski, K | 2 |
| Hanley, DA | 7 |
| Russell, AS | 1 |
| Johnson, JA | 1 |
| Karch, AM | 1 |
| Karch, FE | 1 |
| Välimäki, MJ | 1 |
| Gulson, B | 1 |
| Mizon, K | 1 |
| Smith, H | 1 |
| Eisman, J | 1 |
| Palmer, J | 1 |
| Korsch, M | 1 |
| Donnelly, J | 1 |
| Waite, K | 1 |
| Body, JJ | 1 |
| Gaich, GA | 1 |
| Scheele, WH | 1 |
| Kulkarni, PM | 3 |
| Peretz, A | 1 |
| Dore, RK | 1 |
| Correa-Rotter, R | 1 |
| Papaioannou, A | 4 |
| Cumming, DC | 1 |
| Hodsman, AB | 2 |
| Bone, G | 1 |
| Schnitzer, TJ | 2 |
| Foldes, AJ | 1 |
| Roux, C | 2 |
| Levine, MA | 1 |
| Uebelhart, B | 1 |
| Santora, AC | 5 |
| Kaur, A | 1 |
| Peverly, CA | 1 |
| Orloff, JJ | 1 |
| Srivastava, M | 1 |
| Deal, C | 2 |
| Cao, Y | 1 |
| Mori, S | 1 |
| Mashiba, T | 2 |
| Westmore, MS | 1 |
| Ma, L | 1 |
| Sato, M | 1 |
| Akiyama, T | 1 |
| Shi, L | 1 |
| Komatsubara, S | 1 |
| Miyamoto, K | 1 |
| Norimatsu, H | 1 |
| Drake, WM | 1 |
| Hiorns, MP | 1 |
| Kendler, DL | 1 |
| Ohta, T | 1 |
| Komatsu, S | 1 |
| Tokutake, N | 1 |
| Pfeifer, M | 2 |
| Begerow, B | 2 |
| Pollähne, W | 1 |
| Minne, HW | 3 |
| Fink, HA | 2 |
| Nelson, DB | 1 |
| Kerani, RP | 1 |
| Schreiner, PJ | 1 |
| Zhao, Y | 1 |
| Nevitt, MC | 3 |
| Johnell, O | 1 |
| Jönsson, B | 2 |
| Jönsson, L | 1 |
| Teshima, R | 1 |
| Sohen, S | 2 |
| Thompson, DE | 7 |
| Seeman, E | 3 |
| Haviko, T | 1 |
| Martens, MG | 1 |
| McGowan, JA | 2 |
| Lang, TF | 2 |
| Garnero, P | 4 |
| Bouxsein, ML | 1 |
| Bilezikian, JP | 2 |
| Rosen, CJ | 3 |
| Ettinger, MP | 1 |
| Shukla, VK | 1 |
| Sawka, AM | 2 |
| Ioannidis, G | 2 |
| Olszynski, WP | 3 |
| Brown, JP | 2 |
| Murray, T | 1 |
| Sebaldt, RJ | 3 |
| Petrie, A | 3 |
| Tenenhouse, A | 1 |
| Goldsmith, CH | 3 |
| Shane, E | 3 |
| Addesso, V | 2 |
| Namerow, PB | 1 |
| Lo, SH | 1 |
| Staron, RB | 2 |
| Zucker, M | 1 |
| Pardi, S | 1 |
| Maybaum, S | 2 |
| Mancini, D | 2 |
| Sapuła, RA | 1 |
| Ostrowski, T | 1 |
| Bojar, I | 1 |
| Lufkin, EG | 1 |
| Sarkar, S | 1 |
| Ciaccia, AV | 1 |
| Siddhanti, S | 1 |
| Stock, J | 1 |
| Plouffe, L | 2 |
| Strewler, GJ | 1 |
| Bone, HG | 3 |
| Hosking, D | 1 |
| Devogelaer, JP | 2 |
| Tucci, JR | 3 |
| Emkey, RD | 1 |
| Tonino, RP | 1 |
| Rodriguez-Portales, JA | 1 |
| Downs, RW | 3 |
| Gupta, J | 1 |
| Liberman, UA | 2 |
| Okabe, R | 1 |
| Pérez-López, FR | 1 |
| Keegan, TH | 1 |
| Sellmeyer, DE | 1 |
| Kelsey, JL | 1 |
| Ott, S | 1 |
| Orloff, J | 1 |
| Ewing, SK | 2 |
| Delmas, PD | 6 |
| Rodan, G | 1 |
| Reszka, A | 1 |
| Golub, E | 1 |
| Marx, J | 1 |
| Gourlay, M | 1 |
| Zizic, TM | 1 |
| Hamel, ME | 1 |
| Papadimitropoulos, E | 1 |
| Hagino, H | 1 |
| Chapurlat, RD | 1 |
| Ramsay, P | 1 |
| Maalouf, N | 1 |
| Gottschalk, FA | 1 |
| Pak, CY | 1 |
| Baldini, T | 1 |
| Zraick, V | 2 |
| Root, L | 2 |
| Camacho, NP | 2 |
| Pande, I | 1 |
| Hosking, DJ | 1 |
| Hillier, TA | 1 |
| Pressman, A | 1 |
| Che, M | 1 |
| Sone, T | 1 |
| Christensen, PM | 1 |
| Gyrd-Hansen, D | 1 |
| Kristiansen, IS | 1 |
| Nyman, JA | 2 |
| Kane, RL | 3 |
| McClung, MR | 2 |
| Quandt, SA | 4 |
| Ross, PD | 2 |
| Baran, D | 1 |
| Stevenson, M | 2 |
| Jones, ML | 1 |
| De Nigris, E | 1 |
| Brewer, N | 1 |
| Davis, S | 1 |
| Oakley, J | 1 |
| Boonen, S | 2 |
| Laan, RF | 1 |
| Barton, IP | 1 |
| Davison, KS | 2 |
| Josse, RG | 1 |
| Murray, TM | 1 |
| Tenenhouse, AM | 1 |
| Gafni, A | 1 |
| Thabane, L | 1 |
| Millonig, G | 1 |
| Graziadei, IW | 1 |
| Eichler, D | 1 |
| Pfeiffer, KP | 1 |
| Finkenstedt, G | 1 |
| Muehllechner, P | 1 |
| Koenigsrainer, A | 1 |
| Margreiter, R | 1 |
| Vogel, W | 1 |
| Maricic, M | 1 |
| Hue, T | 1 |
| Nieves, J | 1 |
| Zion, M | 1 |
| Woelfert, L | 1 |
| Luckey, M | 1 |
| Chattopadhyay, A | 1 |
| Liberman, U | 1 |
| McKinney, J | 1 |
| DiMeglio, LA | 1 |
| Peacock, M | 1 |
| Chevrel, G | 1 |
| Schott, AM | 1 |
| Fontanges, E | 1 |
| Charrin, JE | 1 |
| Lina-Granade, G | 1 |
| Duboeuf, F | 1 |
| Arlot, M | 1 |
| Raynal, C | 1 |
| Meunier, PJ | 2 |
| Takada, J | 1 |
| Epstein, S | 1 |
| Emkey, R | 1 |
| Wilson, KM | 1 |
| Hiltbrunner, V | 1 |
| Schimmer, RC | 1 |
| Cohen, A | 1 |
| Namerow, P | 1 |
| Gass, M | 1 |
| Dawson-Hughes, B | 1 |
| Madenci, E | 1 |
| Yilmaz, K | 1 |
| Yilmaz, M | 1 |
| Coskun, Y | 1 |
| Bonnick, S | 1 |
| McClung, M | 3 |
| Burnett, SM | 1 |
| Sebba, A | 1 |
| Kagan, R | 1 |
| Chen, E | 1 |
| de Vernejoul, MC | 1 |
| Rifkin, WD | 1 |
| Atamaz, F | 1 |
| Hepguler, S | 1 |
| Karasu, Z | 1 |
| Kilic, M | 1 |
| Tokat, Y | 1 |
| Chen, P | 1 |
| Misurski, DA | 1 |
| Marcus, R | 3 |
| Vittinghoff, E | 1 |
| Isaia, G | 2 |
| Luisetto, G | 2 |
| Gentilella, R | 2 |
| Agnusdei, D | 2 |
| Iori, N | 1 |
| Nuti, R | 2 |
| Melton, LJ | 2 |
| Briot, K | 1 |
| Dumarcet, N | 1 |
| Bourgoin, M | 1 |
| Chapurlat, R | 2 |
| Christin-Maitre, S | 1 |
| Costagliola, D | 1 |
| Diebolt, V | 1 |
| Lacoin, F | 1 |
| Letombe, B | 1 |
| Oberlin, F | 1 |
| Orcel, P | 1 |
| Ravaud, P | 1 |
| Seret, P | 1 |
| Vogel, JY | 1 |
| Barna, A | 1 |
| Nouyrigat, E | 1 |
| Veyries, ML | 1 |
| Yoldjian, I | 1 |
| Armamento-Villareal, R | 1 |
| Panwar, V | 1 |
| Novack, D | 1 |
| Silverman, SL | 1 |
| Lange, JL | 1 |
| Recker, RR | 1 |
| Kendler, D | 1 |
| Recknor, CP | 1 |
| Rooney, TW | 1 |
| Utian, WH | 1 |
| Lorraine, J | 1 |
| Qu, Y | 1 |
| Gaich, CL | 1 |
| Wong, M | 1 |
| Stock, JL | 1 |
| Levis, S | 2 |
| Satterfield, S | 2 |
| Wehren, LE | 1 |
| Colón-Emeric, CS | 1 |
| Jamal, SA | 1 |
| Ishani, A | 1 |
| Meadows, ES | 1 |
| Klein, R | 1 |
| Rousculp, MD | 1 |
| Smolen, L | 1 |
| Ohsfeldt, RL | 1 |
| Johnston, JA | 1 |
| Shah, I | 1 |
| Johari, A | 1 |
| Erviti, J | 1 |
| Gorricho, J | 1 |
| Anić, B | 1 |
| Grazio, S | 2 |
| Moro Alvarez, MJ | 1 |
| Taylor, BC | 1 |
| Orwoll, ES | 1 |
| Karam, R | 1 |
| Camm, J | 1 |
| Drueke, T | 1 |
| Elder, G | 1 |
| Fukagawa, M | 1 |
| Jorgetti, V | 1 |
| Langman, CB | 1 |
| Moe, S | 1 |
| McCann, L | 1 |
| Wang, AY | 1 |
| Weisinger, J | 1 |
| Wheeler, D | 1 |
| Ito, K | 1 |
| Marín, F | 1 |
| Donley, DW | 1 |
| Taylor, KA | 1 |
| Dalsky, GP | 1 |
| Sambrook, PN | 2 |
| Wada, S | 1 |
| Fukawa, T | 1 |
| Kamiya, S | 1 |
| Cesareo, R | 1 |
| Iozzino, M | 1 |
| Alva, D | 1 |
| Napolitano, C | 1 |
| De Rosa, B | 1 |
| Contini, S | 1 |
| Mallardo, L | 1 |
| Lauria, A | 1 |
| Reda, G | 1 |
| Orsini, A | 1 |
| Adams, J | 1 |
| Borgström, F | 1 |
| Preedy, D | 1 |
| Selby, P | 2 |
| Compston, J | 1 |
| Tanaka, I | 1 |
| Oshima, H | 1 |
| Jansen, JP | 1 |
| Gaugris, S | 1 |
| Bergman, G | 1 |
| Sen, SS | 1 |
| Zambon, A | 1 |
| Baio, G | 1 |
| Mazzaglia, G | 1 |
| Merlino, L | 1 |
| Corrao, G | 1 |
| Wells, GA | 1 |
| Cranney, A | 2 |
| Peterson, J | 1 |
| Boucher, M | 1 |
| Shea, B | 1 |
| Robinson, V | 1 |
| Coyle, D | 2 |
| Tugwell, P | 2 |
| Katayama, K | 1 |
| Matsuno, T | 1 |
| Silvestri, S | 1 |
| Morović-Vergles, J | 1 |
| Cadarette, SM | 1 |
| Katz, JN | 1 |
| Brookhart, MA | 1 |
| Stürmer, T | 1 |
| Stedman, MR | 1 |
| Solomon, DH | 1 |
| Ryder, KM | 1 |
| Moride, Y | 1 |
| Weiss, SR | 1 |
| Bröll, J | 1 |
| Quan, H | 1 |
| Bell, NH | 1 |
| Rodriguez-Portales, J | 1 |
| Dequeker, J | 1 |
| Favus, M | 1 |
| McGrath, H | 1 |
| Keen, RW | 1 |
| Spector, TD | 1 |
| Selby, PL | 1 |
| Sartori, L | 1 |
| Crepaldi, G | 1 |
| Karpf, DB | 2 |
| Genant, HK | 1 |
| Haskell, WL | 1 |
| Torner, JC | 1 |
| Reiss, TF | 1 |
| Harris, ST | 2 |
| Weinstein, RS | 1 |
| Licata, AA | 2 |
| Kimmel, DB | 1 |
| Gertz, BJ | 1 |
| Hale, E | 1 |
| Polvino, WJ | 1 |
| Phillips, A | 1 |
| Shapiro, DR | 1 |
| Johnston, CC | 1 |
| Hirsch, LJ | 1 |
| Oppenheimer, L | 1 |
| Thompson, D | 3 |
| Maughan, KL | 1 |
| Davidson, ET | 1 |
| Coble, YD | 1 |
| Ross, SD | 1 |
| Prostko, M | 1 |
| Heaney, RP | 1 |
| Kopjar, B | 1 |
| Bjørndal, A | 1 |
| Brunelli, MP | 1 |
| Einhorn, TA | 1 |
| Kirby, M | 1 |
| Shiflett, S | 1 |
| Cooke, CE | 1 |
| Scheen, AJ | 1 |
| Gennari, C | 1 |
| Paul, KJ | 1 |
| Beauchesne, MF | 1 |
| Miller, PF | 1 |
| Compston, JE | 1 |
| Ullom-Minnich, P | 1 |
| Klovning, A | 1 |
| Norheim, OF | 1 |
| Cole, RP | 1 |
| Palushock, S | 1 |
| Haboubi, A | 1 |
| Barrett-Connor, E | 1 |
| Scott, J | 2 |
| Riancho, JA | 1 |
| Ritzmann, P | 1 |
| Pols, HA | 1 |
| Stepán, J | 1 |
| Muñoz-Torres, M | 1 |
| Wilkin, TJ | 2 |
| Qin-sheng, G | 1 |
| Galich, AM | 1 |
| Vandormael, K | 1 |
| Yates, AJ | 1 |
| Stych, B | 1 |
| Nevitt, M | 1 |
| Musliner, T | 2 |
| Freedholm, D | 1 |
| Lesser, GT | 1 |
| Mincey, BA | 1 |
| Moraghan, TJ | 1 |
| Perez, EA | 1 |
| Burger, HG | 1 |
| Buist, DS | 1 |
| LaCroix, AZ | 1 |
| Harris, F | 1 |
| Blank, J | 1 |
| Edgerton, D | 1 |
| Rubin, S | 1 |
| Fox, KM | 1 |
| Kamel, HK | 1 |
| Hussain, MS | 1 |
| Tariq, S | 1 |
| Perry, HM | 1 |
| Morley, JE | 1 |
| Halbekath, J | 1 |
| McGarry, KA | 1 |
| Dijkmans, BA | 1 |
| Baran, DT | 1 |
| Ensrud, KC | 1 |
| Scott, JC | 1 |
| Suryawanshi, S | 2 |
| Peiró, S | 1 |
| Ortún Rubio, V | 1 |
| Meneu, R | 1 |
| García-Altés, A | 1 |
| Ridao, M | 1 |
| Bernal Delgado, E | 1 |
| McCormack, J | 1 |
| Lee, KM | 1 |
| Welch, V | 1 |
| McClung, B | 1 |
| Chrischilles, EA | 1 |
| Dasbach, EJ | 1 |
| Rubenstein, LM | 1 |
| Cook, JR | 1 |
| Tabor, HK | 1 |
| Cahill, BC | 1 |
| O'Rourke, MK | 1 |
| Parker, S | 1 |
| Stringham, JC | 1 |
| Karwande, SV | 1 |
| Knecht, TP | 1 |
| Doty, SB | 1 |
| Ilg, WA | 1 |
| Toledano, TR | 1 |
| Faber, H | 1 |
| Li, J | 1 |
| Boivin, G | 1 |
| Meunie, PJ | 1 |
| Kolarov, G | 1 |
| Schneider, DL | 1 |
| Yates, J | 1 |
| Hayashi, Y | 1 |
| Orwoll, E | 1 |
| Daifotis, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis[NCT01575834] | Phase 3 | 7,180 participants (Actual) | Interventional | 2012-03-15 | Completed | ||
| A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis[NCT01631214] | Phase 3 | 4,093 participants (Actual) | Interventional | 2012-05-04 | Completed | ||
| Effects of Romosozumab on Bone Health in Women With Spinal Cord Injury and Osteoporosis[NCT04708886] | Phase 2 | 12 participants (Anticipated) | Interventional | 2021-03-01 | Active, not recruiting | ||
| Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients[NCT05346419] | 33 participants (Actual) | Interventional | 2021-07-01 | Completed | |||
| Vitamin D Improves Osteoporosis in Postmenopausal Women With Denosumab Failure[NCT05372224] | 55 participants (Actual) | Interventional | 2020-06-22 | Completed | |||
| Cyclic Versus Daily Teriparatide on Bone Mass[NCT00668941] | Phase 2 | 140 participants (Anticipated) | Interventional | 2005-09-30 | Active, not recruiting | ||
| Re-establishment of Ovarian Hormonal Function, Delay of Menopause, or Reversal of Early Menopause With High Density (HD PRP), tSVF + PRP, or Cell Enriched tSVF + PRP by Ultrasound Guided Ovarian Injection[NCT04444245] | Phase 1 | 100 participants (Anticipated) | Interventional | 2022-07-15 | Active, not recruiting | ||
| A 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial[NCT00398931] | Phase 3 | 1,099 participants (Actual) | Interventional | 1998-02-28 | Completed | ||
| Resolution of Hyperparathyroidism With High-dose Vitamin D Improves Osteoporosis in Multi-treated Postmenopausal Women[NCT05347082] | 47 participants (Actual) | Interventional | 2021-04-29 | Completed | |||
| Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate[NCT03051620] | 142 participants (Actual) | Observational | 2017-02-01 | Completed | |||
| Quantifying Fatigue of the Respiratory and Swallowing Musculature in Patients With Amyotrophic Lateral Sclerosis[NCT04468191] | 0 participants (Actual) | Interventional | 2021-02-10 | Withdrawn (stopped due to COVID-19 pandemic restrictions for data collection) | |||
| Addressing Vertebral Osteoporosis Incidentally Detected to Prevent Future Fractures: The AVOID FRACTURE Study[NCT00388908] | 240 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| Clinical Trial of Parathyroid Hormone (PTH) and Alendronate in Combination in the Treatment of Osteoporosis[NCT00005005] | Phase 2 | 238 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
| The Denosumab And Teriparatide Administration Study (DATA)[NCT00926380] | Phase 2 | 94 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Prevention of Osteoporosis After Cardiac Transplantation[NCT00000412] | Phase 3 | 149 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation[NCT00297830] | Phase 2/Phase 3 | 111 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Bisphosphonate Users Radiographic Characteristics of the Hip (BURCH) Study[NCT01360099] | 120 participants (Actual) | Observational | 2011-05-04 | Completed | |||
| Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption[NCT01750086] | Phase 4 | 27 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis[NCT00092014] | Phase 3 | 1,053 participants (Actual) | Interventional | 2002-09-01 | Completed | ||
| Genetic Analysis of Familial Cases of Premature Ovarian Failure[NCT01177891] | 110 participants (Actual) | Observational | 2010-10-31 | Completed | |||
| [NCT00035971] | Phase 4 | 0 participants | Interventional | Completed | |||
| Comparison of the Effects of Teriparatide With Those of Alendronate Sodium on Lumbar Spine Bone Mineral Density in Glucocorticoid-Induced Osteoporosis[NCT00051558] | Phase 3 | 428 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| Comparison of 3 Month PTHrP(1-36) and PTH(1-34) on Post-Menopausal Osteoporosis[NCT00853723] | Phase 2 | 105 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203] | Phase 2 | 120 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Finding the Optimal Resistance Training Intensity For Your Bones: A Randomized Controlled Trial (FORTIFY Bones)[NCT05541432] | 324 participants (Anticipated) | Interventional | 2022-09-13 | Recruiting | |||
| Preoperative Optimization Levosimendan in Heart Failure Patients Undergoing Hip Fracture[NCT02972918] | 19 participants (Actual) | Observational | 2014-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.4 |
| Romosozumab | 13.1 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo/Denosumab | 5.5 |
| Romosozumab/Denosumab | 16.6 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.3 |
| Romosozumab | 5.5 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo/Denosumab | 2.3 |
| Romosozumab/Denosumab | 7.3 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.3 |
| Romosozumab | 6.0 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01575834)
Timeframe: Baseline and Month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo/Denosumab | 3.2 |
| Romosozumab/Denosumab | 8.5 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 2.5 |
| Romosozumab | 1.6 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 4.1 |
| Romosozumab/Denosumab | 2.8 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.4 |
| Romosozumab | 0.2 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 0.6 |
| Romosozumab/Denosumab | 0.3 |
A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.5 |
| Romosozumab | 1.0 |
A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 2.8 |
| Romosozumab/Denosumab | 1.9 |
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.8 |
| Romosozumab | 1.1 |
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 3.1 |
| Romosozumab/Denosumab | 1.9 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.8 |
| Romosozumab | 0.5 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 2.5 |
| Romosozumab/Denosumab | 0.7 |
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 2.1 |
| Romosozumab | 1.6 |
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date as recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 3.6 |
| Romosozumab/Denosumab | 2.7 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.3 |
| Romosozumab | 0.03 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. (NCT01575834)
Timeframe: 24 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 0.5 |
| Romosozumab/Denosumab | 0.03 |
"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.~The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height." (NCT01575834)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 1.8 |
| Romosozumab | 0.5 |
"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method.~The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height." (NCT01575834)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/Denosumab | 2.5 |
| Romosozumab/Denosumab | 0.6 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 1.7 |
| Romosozumab/Alendronate | 4.9 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 5.0 |
| Romosozumab/Alendronate | 13.7 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 7.2 |
| Romosozumab/Alendronate | 15.3 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 2.8 |
| Romosozumab/Alendronate | 6.2 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 2.3 |
| Romosozumab/Alendronate | 6.0 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 36
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 2.4 |
| Romosozumab/Alendronate | 6.0 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 36
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 7.8 |
| Romosozumab/Alendronate | 15.2 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 3.5 |
| Romosozumab/Alendronate | 7.2 |
Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. (NCT01631214)
Timeframe: Baseline and month 36
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Alendronate/Alendronate | 3.5 |
| Romosozumab/Alendronate | 7.2 |
All fracture assessments were performed by blinded central imaging readers. Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 13.0 |
| Romosozumab/Alendronate | 9.7 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 5.4 |
| Romosozumab/Alendronate | 3.9 |
Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 9.6 |
| Romosozumab/Alendronate | 7.1 |
A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 0.9 |
| Romosozumab/Alendronate | 0.5 |
A clinical vertebral fracture is a new or worsening vertebral fracture assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms of back pain indicative of a fracture, regardless of trauma severity or whether it is pathologic. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 2.1 |
| Romosozumab/Alendronate | 0.9 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 3.2 |
| Romosozumab/Alendronate | 2.0 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 1.1 |
| Romosozumab/Alendronate | 0.7 |
Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 2.1 |
| Romosozumab/Alendronate | 1.5 |
Major nonvertebral fractures included a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 9.6 |
| Romosozumab/Alendronate | 7.1 |
Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 4.2 |
| Romosozumab/Alendronate | 3.0 |
"A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.~Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method." (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 9.2 |
| Romosozumab/Alendronate | 4.8 |
A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 10.6 |
| Romosozumab/Alendronate | 8.7 |
A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 4.6 |
| Romosozumab/Alendronate | 3.4 |
A nonvertebral fracture was defined as a documented fracture excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 7.8 |
| Romosozumab/Alendronate | 6.3 |
All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures. (NCT01631214)
Timeframe: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 19.1 |
| Romosozumab/Alendronate | 13.0 |
All fractures include any osteoporotic nonvertebral fractures that are not associated with high trauma severity or pathologic fractures and new or worsening vertebral fractures regardless of trauma severity or pathologic fractures. (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 9.2 |
| Romosozumab/Alendronate | 6.5 |
A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4 according to the Genant Semiquantitative Scoring method. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit. Incident vertebral fractures were confirmed by a second independent reader. (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 2.5 |
| Romosozumab/Alendronate | 1.3 |
"New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.~Incident vertebral fractures were confirmed by a second independent reader." (NCT01631214)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 5.0 |
| Romosozumab/Alendronate | 3.2 |
"All fracture assessments were performed by blinded central imaging readers.~New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant Semiquantitative Scoring method based on assessment of x-rays according to the following scale:~Grade 0 (Normal) = no fracture;~Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior);~Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height;~Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.~Incident vertebral fractures were confirmed by a second independent reader using the Semiquantitative method." (NCT01631214)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Alendronate/Alendronate | 8.0 |
| Romosozumab/Alendronate | 4.1 |
"Number of participants in which CTX increased above the least significant change.~The Department of Clinical Biochemistry, Rigshospitalet, Glostrup, Denmark provided the the least significant change for p-CTX > 30%." (NCT03051620)
Timeframe: From baseline to month 24
| Intervention | participants (Number) |
|---|---|
| Study Population | 85 |
We constructed receiver operating characteristic (ROC) curves to evaluate if baseline p-CTX or baseline p-PINP at the time of alendronate discontinuation predicted TH BMD loss above the least significant change at month 12 and/or month 24 at the individual level. (NCT03051620)
Timeframe: Changes in TH BMD after one and two years.
| Intervention | percentage change (Mean) | |
|---|---|---|
| Mean change in TH BMD after one year | Mean change in TH BMD after two years | |
| Study Population | -1.14 | -2.65 |
We constructed receiver operating characteristic (ROC) curves to evaluate if carboxy-terminal collagen crosslinks (CTX) three and six months after stopping alendronate predicted TH BMD loss above the least significant change (LSC) at month 12 at the individual level. (NCT03051620)
Timeframe: Baseline and one year after baseline
| Intervention | percentage change (Mean) | ||
|---|---|---|---|
| Mean change in CTX from baseline to month 3 | Mean change in CTX from baseline to month 6 | Mean change in TH BMD from baseline to month 12 | |
| Study Population | 49 | 64 | 1.14 |
We constructed receiver operating characteristic (ROC) curves to evaluate if changes in p-CTX or p-PINP measured three and six months after stopping alendronate predicted TH BMD loss above the least significant change at month 12 and/or month 24 at the individual level. (NCT03051620)
Timeframe: one and two years after baseline
| Intervention | percentage change (Mean) | |||
|---|---|---|---|---|
| Mean change in PINP from baseline to month 3 | Mean change in PINP from baseline to month 6 | Mean change in TH BMD from baseline to month 12 | Mean change in TH BMD from baseline to month 24 | |
| Study Population | 36 | 54 | -1.14 | -2.65 |
the number of patients who lost BMD beyond the LSC at the lumbar spine (>3%) and total hip (>5%) (NCT03051620)
Timeframe: from baseline to month 24
| Intervention | participants (Number) | |
|---|---|---|
| Spine | Total hip | |
| Study Population | 21 | 26 |
(NCT00926380)
Timeframe: Baseline and 2 years
| Intervention | percent change (Mean) |
|---|---|
| Denosumab ONLY | 8.3 |
| Teriparatide (Forteo®) ONLY | 9.5 |
| Denosumab and Teriparatide (Forteo®) | 12.9 |
BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer. (NCT00297830)
Timeframe: Baseline, 12 months
| Intervention | percent change (Mean) |
|---|---|
| Active Zoledronic Acid and Placebo Alendronate | 0.28 |
| Placebo Zoledronic Acid and Active Alendronate | -0.57 |
| Reference Group | -3.3 |
BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer. (NCT00297830)
Timeframe: Baseline, 12 months
| Intervention | percent change (Mean) |
|---|---|
| Active Zoledronic Acid and Placebo Alendronate | 1.98 |
| Placebo Zoledronic Acid and Active Alendronate | -0.45 |
| Reference Group | -2.6 |
BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer. (NCT00297830)
Timeframe: Baseline, 12 months
| Intervention | percent change (Mean) |
|---|---|
| Active Zoledronic Acid and Placebo Alendronate | 0.39 |
| Placebo Zoledronic Acid and Active Alendronate | -0.21 |
| Reference Group | -2.2 |
The primary outcome was the between-group difference in the teriparatide-induced change in serum c-telopeptide from baseline to week 8. (NCT01750086)
Timeframe: 8 weeks
| Intervention | percentage of change in CTX (Mean) |
|---|---|
| Denosumab 60mg Subcutaneous Injection | -7 |
| Alendronate 70mg Weekly x 8 Weeks | 43 |
change from baseline at endpoint in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 18 month endpoint
| Intervention | grams per square centimeters (Least Squares Mean) |
|---|---|
| Teriparatide | 0.059 |
| Alendronate | 0.028 |
change from baseline at endpoint in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 18 month endpoint
| Intervention | grams per square centimeters (Least Squares Mean) |
|---|---|
| Teriparatide | 0.056 |
| Alendronate | 0.023 |
Clinical vertebral fracture was defined as a radiographically confirmed fracture that was associated with symptoms such as back pain. (NCT00051558)
Timeframe: 36 months
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Any Fracture | Nonvertebral Fracture | Vertebral Fracture | Clinical Vertebral Fracture | Nonvertebral Fragility Fracture | Severity-Radiographic Vertebral Fracture: Mild | Severity-Radiographic Vertebral Fracture: Moderate | Severity-Radiographic Vertebral Fracture: Severe | |
| Alendronate | 27 | 15 | 13 | 4 | 5 | 7 | 2 | 4 |
| Teriparatide | 19 | 16 | 3 | 0 | 9 | 1 | 2 | 0 |
change from baseline in bone mineral density of the femoral neck as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 18, 24, 36 months, and 18 and 36 month endpoints
| Intervention | grams per square centimeters (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Change, baseline to 36 month endpoint(N=185,N=177) | Change from baseline at 36 months(N=120,N=113) | Change from baseline at 24 months(N=135,N=131) | Change, baseline to 18 month endpoint(N=185,N=176) | Change from baseline at 18 months (N=156,N=145) | |
| Alendronate | 0.017 | 0.021 | 0.015 | 0.014 | 0.017 |
| Teriparatide | 0.033 | 0.041 | 0.030 | 0.024 | 0.028 |
change from baseline in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 24 and 36 months and Endpoint at 36 months
| Intervention | grams per square centimeters (Least Squares Mean) | ||
|---|---|---|---|
| Change, baseline to 36 month endpoint(N=198,N=195) | Change from baseline at 36 months (N=123, N=112) | Change from baseline at 24 months (N=136, N=131) | |
| Alendronate | 0.034 | 0.044 | 0.043 |
| Teriparatide | 0.073 | 0.090 | 0.081 |
change from baseline in bone mineral density of the total hip as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 18, 24, 36 months, and 18 and 36 month endpoints
| Intervention | grams per square centimeters (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Change, baseline to 36 month endpoint(N=185,N=177) | Change from baseline at 36 months(N=120,N=113) | Change from baseline at 24 months(N=135,N=131) | Change, baseline to 18 month endpoint(N=185,N=176) | Change from baseline at 18 months (N=156,N=144) | |
| Alendronate | 0.017 | 0.020 | 0.018 | 0.017 | 0.018 |
| Teriparatide | 0.032 | 0.037 | 0.034 | 0.026 | 0.027 |
(NCT00051558)
Timeframe: 1, 6, 18, and 36 months
| Intervention | percent (Mean) | |||
|---|---|---|---|---|
| Percent change from baseline at Month 1(N=65,N=78) | Percent change from baseline at Month 6(N=66,N=76) | Percent change from baseline at Month18(N=54,N=65) | Percent change from baseline at Month36(N=44,N=49) | |
| Alendronate | 0.5 | -7.2 | -4.1 | 20.6 |
| Teriparatide | 35.0 | 52.3 | 34.4 | 44.7 |
(NCT00051558)
Timeframe: 1, 6, 18, and 36 months
| Intervention | percent (Mean) | |||
|---|---|---|---|---|
| Percent change from baseline at Month1(N=94,N=100) | Percent change from baseline at Month 6(N=84,N=88) | Percent change from baseline at Month18(N=77,N=77) | Percent change from baseline at Month36(N=56,N=58) | |
| Alendronate | -5.2 | -33.6 | -25.0 | -19.6 |
| Teriparatide | 147.1 | 120.0 | 108.9 | 62.1 |
(NCT00051558)
Timeframe: 1, 6, 18, and 36 months
| Intervention | percent (Mean) | |||
|---|---|---|---|---|
| Percent change from baseline at Month 1(N=66,N=78) | Percent change from baseline at Month 6(N=67,N=76) | Percent change from baseline at Month18(N=55,N=65) | Percent change from baseline at Month36(N=45,N=49) | |
| Alendronate | -8.8 | -22.3 | -21.3 | -15.4 |
| Teriparatide | 48.2 | 10.5 | 5.1 | -1.3 |
(NCT00051558)
Timeframe: 1, 6, 18, and 36 months
| Intervention | percent (Mean) | |||
|---|---|---|---|---|
| Percent change from baseline at Month 1(N=98,N=99) | Percent change from baseline at Month 6(N=86,N=85) | Percent change from baseline at Month18(N=77,N=76) | Percent change from baseline at Month36(N=59,N=57) | |
| Alendronate | -14.8 | -43.2 | -35.8 | -20.2 |
| Teriparatide | 107.0 | 130.8 | 86.3 | 61.7 |
(NCT00051558)
Timeframe: 1, 6, 18, and 36 months
| Intervention | percent (Mean) | |||
|---|---|---|---|---|
| Percent change from baseline at Month 1(N=70,N=79) | Percent change from baseline at Month 6(N=66,N=75) | Percent change from baseline at Month18(N=64,N=71) | Percent change from baseline at Month36(N=49,N=48) | |
| Alendronate | -38.6 | -42.4 | -47.5 | -16.2 |
| Teriparatide | 29.0 | 66.8 | 29.1 | 30.7 |
change from baseline in bone mineral density of the femoral neck as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 12, 18, 24, and 36 months
| Intervention | grams per square centimeters (Least Squares Mean) | |||
|---|---|---|---|---|
| Change from baseline at Month 36 (N=120,N=113) | Change from baseline at Month 24 (N=135,N=131) | Change from baseline at Month 18 (N=156,N=145) | Change from baseline at Month 12 (N=167,N=158) | |
| Alendronate | 0.021 | 0.015 | 0.017 | 0.012 |
| Teriparatide | 0.041 | 0.030 | 0.028 | 0.026 |
change from baseline in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 3, 6, 12, and 18 months
| Intervention | grams per square centimeters (Least Squares Mean) | |||
|---|---|---|---|---|
| Change from baseline at Month 18 (N=127,N=119) | Change from baseline at Month 12 (N=139,N=129) | Change from baseline at Month 6 (N=147,N=139) | Change from baseline at Month 3 (N=149,N=150) | |
| Alendronate | 0.027 | 0.024 | 0.015 | 0.012 |
| Teriparatide | 0.062 | 0.052 | 0.031 | 0.017 |
change from baseline in bone mineral density of the lumbar spine as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 3, 6, 12, 18, 24, 36 months
| Intervention | grams per square centimeters (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Change from baseline at Month 36 (N=123,N=112) | Change from baseline at Month 24 (N=136,N=131) | Change from baseline at Month 18 (N=156,N=148) | Change from baseline at Month 12 (N=170,N=159) | Change from baseline at Month 6 (N=178,N=173) | Change from baseline at Month 3 (N=183,N=184) | |
| Alendronate | 0.044 | 0.043 | 0.031 | 0.028 | 0.018 | 0.012 |
| Teriparatide | 0.090 | 0.081 | 0.066 | 0.054 | 0.034 | 0.019 |
change from baseline in bone mineral density of the total hip as assessed by dual energy X-ray absorptiometry (DXA) (NCT00051558)
Timeframe: 12, 18, 24, and 36 months
| Intervention | grams per square centimeters (Least Squares Mean) | |||
|---|---|---|---|---|
| Change from baseline at 36 Months (N=120, N=113) | Change from baseline at 24 Months (N=135, N=131) | Change from baseline at 18 Months (N=156, N=145) | Change from baseline at 12 Months (N=167, N=158) | |
| Alendronate | 0.020 | 0.018 | 0.018 | 0.014 |
| Teriparatide | 0.037 | 0.034 | 0.027 | 0.022 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | -0.35 |
| PTHrP 600 mcg/Day | -0.34 |
| PTH 20 mcg/Day | -0.82 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | 0.91 |
| PTHrP 600 mcg/Day | 0.54 |
| PTH 20 mcg/Day | 0.61 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | -0.48 |
| PTHrP 600 mcg/Day | -0.99 |
| PTH 20 mcg/Day | -0.97 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | 1.89 |
| PTHrP 600 mcg/Day | 1.52 |
| PTH 20 mcg/Day | 2.17 |
(NCT00853723)
Timeframe: 90 days
| Intervention | Percent change from baseline (Mean) |
|---|---|
| PTHrP 400 mcg/Day | 0.68 |
| PTHrP 600 mcg/Day | 0.72 |
| PTH 20 mcg/Day | 0.54 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | pg/ml (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 42.51 | 65.25 | 67.29 | 58.15 | 53.73 |
| PTHrP 400 mcg/Day | 49.06 | 84.92 | 76.04 | 67.85 | 64.36 |
| PTHrP 600 mcg/Day | 42.49 | 63.07 | 65.15 | 57.02 | 55.08 |
(NCT00853723)
Timeframe: 90 days
| Intervention | mg/gm creatinine (Mean) | |
|---|---|---|
| Baseline | Day 90 | |
| PTH 20 mcg/Day | 209.99 | 232.48 |
| PTHrP 400 mcg/Day | 206.37 | 260.46 |
| PTHrP 600 mcg/Day | 213.07 | 235.25 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | percentage change from baseline (Mean) | |||
|---|---|---|---|---|
| Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 4.87 | 13.89 | 52.98 | 92.46 |
| PTHrP 400 mcg/Day | -12.40 | 1.60 | 4.13 | 32.65 |
| PTHrP 600 mcg/Day | 10.25 | 9.59 | 14.38 | 25.65 |
(Serum Creatinine X Urine Calcium)/(Serum Calcium X Urine Creatinine) (NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | % excreted (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 2.30 | 2.55 | 2.92 | 2.95 | 3.37 |
| PTHrP 400 mcg/Day | 2.38 | 3.42 | 3.27 | 3.38 | 3.10 |
| PTHrP 600 mcg/Day | 2.71 | 4.18 | 3.74 | 2.89 | 2.89 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | percentage change from baseline (Mean) | |||
|---|---|---|---|---|
| Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 60.67 | 97.27 | 125.46 | 171.49 |
| PTHrP 400 mcg/Day | 32.54 | 48.89 | 34.71 | 46.07 |
| PTHrP 600 mcg/Day | 23.51 | 83.14 | 87.39 | 84.09 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | mg/dl (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 4.09 | 4.13 | 4.19 | 4.28 | 4.10 |
| PTHrP 400 mcg/Day | 4.0 | 3.78 | 3.87 | 4.02 | 4.05 |
| PTHrP 600 mcg/Day | 3.93 | 3.68 | 3.71 | 3.97 | 3.98 |
(NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | mg/dl (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90, time 0 | Day 90, time 3 hours | day 90, time 6 hours | |
| PTH 20 mcg/Day | 9.49 | 9.57 | 9.55 | 9.58 | 9.44 | 9.75 | 9.78 |
| PTHrP 400 mcg/Day | 9.48 | 9.95 | 9.73 | 9.71 | 9.56 | 9.90 | 9.90 |
| PTHrP 600 mcg/Day | 9.51 | 9.87 | 9.67 | 9.61 | 9.45 | 9.76 | 9.81 |
"Fractional tubular reabsorption of phosphate (TRP) = 1-{(U phos/P phos) x ( P creat/U creat)} if TRP < or = 0.86 then TMP/GFR = TRP x P phos if TRP > 0.86 then TMP/GFR = 0.3 x TRP/{1-(0.8 x TRP)} x P phos~U= urine, P = plasma" (NCT00853723)
Timeframe: Baseline, Day 15, Day 30, Day 60, Day 90
| Intervention | mg/dl (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Day 15 | Day 30 | Day 60 | Day 90 | |
| PTH 20 mcg/Day | 3.96 | 4.18 | 4.03 | 4.28 | 4.00 |
| PTHrP 400 mcg/Day | 3.80 | 3.78 | 3.88 | 4.02 | 4.11 |
| PTHrP 600 mcg/Day | 3.71 | 3.47 | 3.61 | 3.84 | 3.90 |
101 reviews available for alendronate and Bone Fractures
| Article | Year |
|---|---|
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Hum | 2022 |
Novel formulations of oral bisphosphonates in the treatment of osteoporosis.
Topics: Alendronate; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid | 2022 |
Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Fract | 2023 |
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Child; Cystic Fibrosis; Diphosphonates; Female | 2023 |
The impacts of menopausal hormone therapy on longer-term health consequences of ovarian hormone deficiency.
Topics: Alendronate; Estradiol; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Menopause; Pr | 2023 |
Treatment for osteoporosis in people with beta-thalassaemia.
Topics: Adult; Alendronate; beta-Thalassemia; Child; Clodronic Acid; Denosumab; Diphosphonates; Female; Frac | 2023 |
Efficacy and safety of medications for osteoporosis in kidney transplant recipients or patients with chronic kidney disease: A meta-analysis.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; | 2023 |
Long-term consequences of osteoporosis therapy with bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Oste | 2023 |
Romosozumab: A Review in Postmenopausal Osteoporosis.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Clinical Trials | 2020 |
Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosp | 2013 |
Postmenopausal osteoporosis.
Topics: Accidental Falls; Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density C | 2013 |
Prevention and treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Remodeli | 2014 |
A review of osteoporosis management in younger premenopausal women.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Evidence-Based Medicine; Female; | 2014 |
[Glucocorticoid and bone].
Topics: Administration, Ophthalmic; Adult; Aged; Alendronate; Animals; Bone Density; Bone Density Conservati | 2014 |
Alendronate: new formulations of an old and effective drug to improve adherence avoiding upper gastrointestinal side effects.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Female; Fractures | 2014 |
Osteoporosis: the emperor has no clothes.
Topics: Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Evidence-Based Medicine; Female; | 2015 |
Osteoporosis: the evolution of a diagnosis.
Topics: Absorptiometry, Photon; Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Fracture | 2015 |
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans | 2015 |
The use of bisphosphonates in women: when to use and when to stop.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Iban | 2015 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic A | 2016 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relations | 2008 |
Treatment of postmenopausal osteoporosis in women: a systematic review.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone | 2008 |
[Alendronate].
Topics: Activities of Daily Living; Alendronate; Bone Density; Bone Density Conservation Agents; Evidence-Ba | 2008 |
Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Organometall | 2009 |
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Frac | 2009 |
Denosumab update.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Bone | 2009 |
[A-TOP research group/JOINT program].
Topics: Alendronate; Bone Density Conservation Agents; Cholecalciferol; Drug Therapy, Combination; Evidence- | 2009 |
[Hormones and osteoporosis update. Glucocorticoids and bone].
Topics: Alendronate; Animals; Calcium; Fractures, Bone; Glucocorticoids; Humans; Hydrocortisone; Osteoporosi | 2009 |
Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.
Topics: Alendronate; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone | 2011 |
Fracture prevention in postmenopausal women.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Calcium, Dietary; Etidronic Aci | 2011 |
What is the optimal duration of bisphosphonate therapy?
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Femoral F | 2011 |
Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; | 2012 |
Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density; Bone Density Con | 2013 |
Osteoporosis in elderly: prevention and treatment.
Topics: Aged; Alendronate; Etidronic Acid; Exercise; Female; Fractures, Bone; Hormone Replacement Therapy; H | 2002 |
[Pharmacological and clinical properties of alendronate sodium hydrate].
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clinical Trials as Topic; Depression, Chemical; | 2002 |
[Osteoporosis: prevention of bone loss and fractures].
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Diseases, Metabolic; Diagnosis, D | 2002 |
[Clinical trials of alendronate].
Topics: Alendronate; Clinical Trials as Topic; Fractures, Bone; Humans; Osteoporosis | 2003 |
[Treatment of osteoporosis provided from the orthopaedic surgeon's standpoint].
Topics: Alendronate; Etidronic Acid; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid | 2003 |
[Osteoporosis in men].
Topics: Alendronate; Androgens; Calcium Channel Blockers; Diagnosis, Differential; Etidronic Acid; Fractures | 2003 |
[Rehabilitation in osteoporosis].
Topics: Alendronate; Ergonomics; Exercise Therapy; Female; Fractures, Bone; Humans; Male; Osteoporosis; Pain | 2003 |
Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.
Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogen Antagonists; Femal | 2003 |
Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Topics: Aged; Alendronate; Calcium Channel Blockers; Diphosphonates; Estrogen Replacement Therapy; Etidronic | 2003 |
The use of intermittent human parathyroid hormone as a treatment for osteoporosis.
Topics: Alendronate; Bone Density; Drug Administration Schedule; Female; Fractures, Bone; Humans; Lumbar Ver | 2004 |
What predicts early fracture or bone loss on bisphosphonate therapy?
Topics: Alendronate; Etidronic Acid; Female; Forecasting; Fractures, Bone; Humans; Middle Aged; Osteoporosis | 2003 |
Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial.
Topics: Alendronate; Biomarkers; Bone Density; Calcitonin; Diphosphonates; Estrogens; Female; Fractures, Bon | 2004 |
[Treatment of osteoporosis--a new paradigm].
Topics: Alendronate; Bone Density; Cholecalciferol; Diphosphonates; Drug Design; Fractures, Bone; Humans; Os | 2004 |
[Bone mass measurement and evaluation of therapeutical response].
Topics: Absorptiometry, Photon; Aging; Alendronate; Biomarkers; Bone Density; Calcium; Estrogen Replacement | 2004 |
[Serum beta-CTx(beta-CrossLaps)].
Topics: Alendronate; Biomarkers; Bone Density; Bone Resorption; Collagen; Collagen Type I; Fractures, Bone; | 2004 |
[Treatment of osteoporosis with alendronate].
Topics: Alendronate; Apoptosis; Bone Density; Bone Resorption; Clinical Trials as Topic; Fractures, Bone; Hu | 2004 |
Postmenopausal osteoporosis and alendronate.
Topics: Aged; Alendronate; Bone Density; Bone Resorption; Female; Femur Neck; Fractures, Bone; Humans; Lumba | 2004 |
Bone safety of long-term bisphosphonate treatment.
Topics: Alendronate; Bone and Bones; Bone Diseases; Bone Remodeling; Calcification, Physiologic; Diphosphona | 2004 |
Pharmacologic prevention of osteoporotic fractures.
Topics: Aged; Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; | 2004 |
[Who are the candidates for the treatment by raloxifen ?].
Topics: Age Factors; Alendronate; Bone and Bones; Bone Density; Diet Therapy; Drug Therapy, Combination; Exe | 2004 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, C | 2005 |
[Increase in bone mineral density and its effect on fracture risk].
Topics: Alendronate; Bone Density; Bone Remodeling; Fluorides; Fractures, Bone; Humans; Meta-Analysis as Top | 2005 |
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysi | 2005 |
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Middle | 2005 |
Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Male; M | 2005 |
Glucocorticoid-induced osteoporosis: treatment options and guidelines.
Topics: Alendronate; Bone Density; Bone Resorption; Diphosphonates; Etidronic Acid; Exercise; Female; Fractu | 2005 |
[Application of anti-resorptive drugs for the treatment of osteoporosis].
Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; | 2006 |
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administra | 2006 |
Preventing osteoporosis-related fractures: an overview.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone D | 2006 |
Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; | 2006 |
[Drug treatment of postmenopausal osteoporosis. What's New in 2006].
Topics: Absorptiometry, Photon; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Body Mass Index; B | 2006 |
[Osteoporosis: Optimizing treatment strategy].
Topics: Age Factors; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcium, | 2006 |
[Current osteoporosis treatment: reasons for adding vitamin D to alendronate].
Topics: Alendronate; Bone Density Conservation Agents; Drug Combinations; Female; Fractures, Bone; Humans; O | 2006 |
Pharmacological treatment of osteoporosis for people over 70.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium; Diphosphonates; Etidronic Acid; Female; Fractu | 2007 |
[Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials as Top | 2007 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosph | 2007 |
[FACT study].
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double- | 2007 |
[Evidence of alendronate treatment for osteoporosis].
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Colla | 2007 |
Alendronate for the treatment of osteoporosis in men.
Topics: Alendronate; Bone Density Conservation Agents; Fractures, Bone; Glucocorticoids; Humans; Male; Osteo | 2008 |
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Fractures, Spontaneous; Hip | 2008 |
[Alendronate and vitamin D (Fosavance): persistence, adherence and importance of vitamin D].
Topics: Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Osteoporosis, Postme | 2007 |
Alendronate--a new bisphosphonate.
Topics: Alendronate; Bone Density; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Treatment Outcome | 1996 |
Osteoporosis treatment: focusing the target.
Topics: Aged; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; O | 1996 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; | 1997 |
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Middle A | 1997 |
Alendronate treatment for osteoporosis: a review of the clinical evidence.
Topics: Alendronate; Bone Density; Fractures, Bone; Humans; Osteoporosis; Safety; Treatment Outcome | 1996 |
Osteoporosis: trials and tribulations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Estrogen Replaceme | 1997 |
Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
Topics: Adult; Aged; Alendronate; Bone and Bones; Bone Density; Calcification, Physiologic; Clinical Trials, | 1998 |
Medical management of osteoporosis. Fracture prevention.
Topics: Aged; Alendronate; Benzothiadiazines; Bone Density; Calcitonin; Calcium; Calcium, Dietary; Diuretics | 1998 |
Osteoporosis: a focus on treatment.
Topics: Accidental Falls; Aged; Aging; Alendronate; Bone Density; Calcitonin; Contraindications; Estrogen Re | 1997 |
A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Female; Fractures, Bone; Humans; Osteoporosis; Spin | 1998 |
Bisphosphonates and osteoporosis treatment in Italy.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Fem | 1998 |
Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials.
Topics: Alendronate; Calcitonin; Calcitriol; Calcium; Calcium Fluoride; Evidence-Based Medicine; Fractures, | 1999 |
Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
Topics: Aging; Alendronate; Bone Density; Clinical Trials as Topic; Data Collection; Etidronic Acid; Female; | 1999 |
Prevention of osteoporosis and fractures.
Topics: Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Female; | 1999 |
Prevention and treatment of osteoporosis in women with breast cancer.
Topics: Aged; Alendronate; Bone Density; Breast Neoplasms; Calcitonin; Diphosphonates; Female; Fractures, Bo | 2000 |
[Drug treatment for the treatment of primary osteoporosis].
Topics: Alendronate; Fluorides; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective E | 2000 |
Postmenopausal osteoporosis. Strategies for preventing bone loss, avoiding fracture.
Topics: Aged; Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Female; Fractures, Bone; Hum | 2000 |
[Effect of anti-osteoporosis agents on the incidence of vertebral fractures].
Topics: Alendronate; Bone Density; Calcitonin; Calcium Channel Blockers; Densitometry; Etidronic Acid; Femal | 2000 |
Osteoporosis: which current treatments reduce fracture risk?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Calcium Channel Blockers; Estrogen R | 2000 |
[Therapeutic strategies for osteoporosis].
Topics: Accidental Falls; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calci | 2000 |
Treatment of osteoporosis with bisphosphonates.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Fem | 2001 |
Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation.
Topics: Aged; Aged, 80 and over; Alendronate; Calcitonin; Cost-Benefit Analysis; Female; Fractures, Bone; Hu | 2001 |
Pharmacologic therapy for the treatment and prevention of osteoporosis.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Etidronic | 2001 |
Update on alendronate for osteoporosis: once-weekly dosing.
Topics: Alendronate; Animals; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administratio | 2001 |
[New aspects and opportunities in the clinical use of fosamax].
Topics: Administration, Oral; Aged; Alendronate; Bulgaria; Female; Fractures, Bone; Humans; Middle Aged; Ost | 2001 |
[Advancement of treatment for osteoporosis].
Topics: Alendronate; Bone Density; Cholecalciferol; Clinical Trials as Topic; Estrogen Replacement Therapy; | 2002 |
Treatment of male osteoporosis: recent advances with alendronate.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Resorption; Calcium; Female; Fractures, Bone; Humans; H | 2002 |
71 trials available for alendronate and Bone Fractures
| Article | Year |
|---|---|
Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Female; Femur N | 2022 |
Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Female; F | 2020 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Topics: Aged; Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Bone Remo | 2017 |
Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis.
Topics: Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Drug Administration Schedul | 2018 |
ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
Topics: Adolescent; Alendronate; Bone Density; Child; Child, Preschool; Diphosphonates; Female; Follow-Up St | 2018 |
Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Topics: Administration, Oral; Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diph | 2018 |
Administration of teriparatide for four years cyclically compared to two years daily in treatment Naïve and alendronate treated women.
Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Cohort Studies; Drug | 2019 |
Effect of Alendronic Acid on Fracture Healing: A Multicenter Randomized Placebo-Controlled Trial.
Topics: Alendronate; Female; Fracture Healing; Fractures, Bone; Humans; Male; Medication Adherence; Middle A | 2019 |
Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Diphosphonates; Drug Administration Schedule; | 2013 |
Comparing tolerability and efficacy of generic versus brand alendronate: a randomized clinical study in postmenopausal women with a recent fracture.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cross-Over Studies; Double-Blind Method; Drugs, | 2013 |
Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone | 2014 |
Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Fractures, Bone; Gluc | 2016 |
Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate.
Topics: Alendronate; Bone Density; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausa | 2016 |
Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blin | 2008 |
Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy.
Topics: Adolescent; Adult; Alendronate; Autoimmune Diseases; Bone Density; Bone Density Conservation Agents; | 2008 |
Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Calcification, | 2010 |
Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; | 2009 |
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind M | 2010 |
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind M | 2010 |
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind M | 2010 |
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind M | 2010 |
Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femur Neck; Fractures, Bone; Hi | 2010 |
Efficacy of strontium ranelate on bone mineral density in men with osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Body Height; Bone Density; Bone Density Conservati | 2010 |
Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Topics: Administration, Oral; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Cohort Stu | 2010 |
Low acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation setting.
Topics: Acute Disease; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcium; Chol | 2010 |
The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Confounding Factors, Epidemiologic; Diphosphonat | 2011 |
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
Topics: Adolescent; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Child; Chil | 2011 |
Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.
Topics: Alendronate; Bone Density Conservation Agents; Fractures, Bone; Hydroxycholecalciferols; Japan; Oste | 2011 |
The safety and efficacy of early-stage bi-weekly alendronate to improve bone mineral density and bone turnover in chinese post-menopausal women at risk of osteoporosis.
Topics: Adult; Aged; Alendronate; Alkaline Phosphatase; Asian People; Biomarkers; Bone Density; Bone Density | 2011 |
Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.
Topics: Aged; Alendronate; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cohor | 2011 |
Bioavailability and short-term tolerability of alendronate in glucocorticoid-treated children.
Topics: Administration, Oral; Adolescent; Alendronate; Biological Availability; Bone Density Conservation Ag | 2011 |
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Body Height; Bone and | 2002 |
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density; Bone Resorption; Co | 2002 |
Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT).
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alendronate; Disability Evaluation; Female; Fol | 2003 |
The effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention Trial.
Topics: Aged; Aged, 80 and over; Alendronate; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Po | 1999 |
The antifracture efficacy of alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Double-Blind Method; Female; Fractures, Bone; Hu | 1999 |
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodel | 2003 |
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodel | 2003 |
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodel | 2003 |
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodel | 2003 |
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Calcium; Collagen; Collagen Type I; Female; | 2004 |
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Calcium; Collagen; Collagen Type I; Female; | 2004 |
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Calcium; Collagen; Collagen Type I; Female; | 2004 |
Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Density; Bone Resorption; Calcitriol; Calcium; Collagen; Collagen Type I; Female; | 2004 |
Ten years' experience with alendronate for osteoporosis in postmenopausal women.
Topics: Aged; Alendronate; Body Height; Bone Density; Bone Remodeling; Double-Blind Method; Female; Fracture | 2004 |
Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Body Mass Index; Bone Density; Diabetes Mellitus, | 2004 |
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density | 2004 |
Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Remodeling; Female; Fractures, Bone; H | 2005 |
Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Double-Blind Method; Female; Fractu | 2005 |
Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; | 2005 |
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Calcium Carbonate; | 2005 |
Daily and cyclic parathyroid hormone in women receiving alendronate.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Bone Remodeling; Drug Administration Schedule; Drug The | 2005 |
Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
Topics: Administration, Oral; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Ch | 2006 |
Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodel | 2006 |
Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Alendronate; Biomarkers; Bone Density; Bone Den | 2006 |
Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover.
Topics: Adult; Alendronate; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone | 2006 |
Alendronate treatment in osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Alendronate; Alkaline Phosphatase; Bone Density; Bone Density Conservation A | 2006 |
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
Topics: Aged; Alendronate; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Femur | 2006 |
The prevention of bone fractures after liver transplantation: experience with alendronate treatment.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femur; Fractures, Bone; | 2006 |
Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Female; Frac | 2006 |
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; Female; | 2007 |
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; Female; | 2007 |
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; Female; | 2007 |
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Double-Blind Method; Female; | 2007 |
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Topics: Aged; Alendronate; Biomarkers; Biopsy; Bone Density; Bone Density Conservation Agents; Bone Remodeli | 2006 |
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Topics: Aged; Alendronate; Biomarkers; Biopsy; Bone Density; Bone Density Conservation Agents; Bone Remodeli | 2006 |
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Topics: Aged; Alendronate; Biomarkers; Biopsy; Bone Density; Bone Density Conservation Agents; Bone Remodeli | 2006 |
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Topics: Aged; Alendronate; Biomarkers; Biopsy; Bone Density; Bone Density Conservation Agents; Bone Remodeli | 2006 |
Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Creatinine; Fe | 2007 |
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bo | 2007 |
Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density Con | 2008 |
Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Calcium; Female; Fractures, Bone; Humans; Lipid Metabol | 2008 |
Does a history of non-vertebral fracture identify women without osteoporosis for treatment?
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Chi-Square Dis | 2008 |
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Topics: Aged; Aged, 80 and over; Alendronate; Body Height; Bone Density; Calcium Carbonate; Diphosphonates; | 1995 |
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Topics: Aged; Aged, 80 and over; Alendronate; Body Height; Bone Density; Calcium Carbonate; Diphosphonates; | 1995 |
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Topics: Aged; Aged, 80 and over; Alendronate; Body Height; Bone Density; Calcium Carbonate; Diphosphonates; | 1995 |
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Topics: Aged; Aged, 80 and over; Alendronate; Body Height; Bone Density; Calcium Carbonate; Diphosphonates; | 1995 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Femur Neck; Follow-Up Studies; Fractures | 1996 |
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
Topics: Aged; Aged, 80 and over; Alendronate; Biopsy; Bone and Bones; Bone Density; Dose-Response Relationsh | 1997 |
Alendronate increased bone mineral density but did not reduce new fractures in glucocorticoid induced osteoporosis.
Topics: Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Glucocorticoids; Humans; Osteopo | 1999 |
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Analysis of Variance; Biomarkers; | 1999 |
Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Digestive System; Double-Blind Method; Duodenal | 2000 |
Inclusion of older women in randomized clinical trials: factors associated with taking study medication in the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Comorbidity; Depression; Female; Follow-Up Studies; Fractures, | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Risk of mortality following clinical fractures.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hip | 2000 |
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.
Topics: Aged; Alendronate; Cohort Studies; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Os | 2000 |
The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Chi-Square Distribution; Confidence Intervals; Cost Savings; D | 2001 |
Prevention of bone loss and fracture after lung transplantation: a pilot study.
Topics: Absorptiometry, Photon; Adult; Alendronate; Bone Density; Diphosphonates; Drug Administration Schedu | 2001 |
Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study.
Topics: Aged; Alendronate; Body Height; Body Mass Index; Fractures, Bone; Humans; Male; Middle Aged; Osteopo | 2001 |
Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial.
Topics: Aged; Alendronate; Double-Blind Method; Female; Follow-Up Studies; Fractures, Bone; Humans; Multiple | 2002 |
184 other studies available for alendronate and Bone Fractures
| Article | Year |
|---|---|
Development of Atypical Ulnar Fracture is Associated with Bisphosphonate Therapy and Severe Spinal Deformity: A Case Report.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Acceptability and engagement amongst patients on oral and intravenous bisphosphonates for the treatment of osteoporosis in older adults.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans | 2022 |
Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bo | 2023 |
Acetabular and sacral insufficiency fractures in a patient with a long-term history of Alendronate consumption; a case report.
Topics: Acetabulum; Alendronate; Diphosphonates; Female; Fractures, Bone; Fractures, Stress; Humans; Middle | 2023 |
Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Fractures, B | 2023 |
Eleven years secular trend of the initiation of anti-osteoporosis medications and subsequent fractures in Taiwan: From 2008 to 2018.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Male; Osteopor | 2023 |
Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Cost-Effectiveness Analy | 2023 |
Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Etidronic Acid | 2023 |
Simple methods for the estimation and sensitivity analysis of principal strata effects using marginal structural models: Application to a bone fracture prevention trial.
Topics: Aged; Alendronate; Biometry; Clinical Trials as Topic; Drug Interactions; Female; Fractures, Bone; H | 2019 |
The Supreme Court's Latest Ruling on Drug Liability and its Implications for Future Failure-to-Warn Litigation.
Topics: Alendronate; Disclosure; Drug Industry; Drug Labeling; Femur; Fractures, Bone; Humans; Liability, Le | 2019 |
T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Female; Fractur | 2020 |
The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: A protocol for systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphos | 2021 |
Antiresorptive treatment and talar collapse after displaced fractures of the talar neck: a long-term follow-up of 19 patients.
Topics: Adolescent; Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Fem | 2021 |
Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Female; Fractures, B | 2017 |
Impairment of cold injury-induced muscle regeneration in mice receiving a combination of bone fracture and alendronate treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Cold Injury; Disease Models, Animal; Fractur | 2017 |
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Etidronic | 2017 |
Effects of local alendronate administration on bone defect healing. Histomorphometric and radiological evaluation in a rabbit model.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Regeneration; Disease Models, Animal; F | 2017 |
Bone diseases: Romosozumab - on track or derailed?
Topics: Alendronate; Antibodies, Monoclonal; Female; Fractures, Bone; Humans; Osteoporosis | 2017 |
Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment.
Topics: Aged; Alendronate; Asian People; Bone and Bones; Bone Density; Bone Remodeling; Drug Therapy, Combin | 2018 |
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density; Bone Density Conservation Agents; Female; Fractur | 2018 |
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
Topics: Alendronate; Antibodies, Monoclonal; Female; Fractures, Bone; Humans; Osteoporosis | 2018 |
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
Topics: Alendronate; Antibodies, Monoclonal; Female; Fractures, Bone; Humans; Osteoporosis | 2018 |
Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
Topics: Alendronate; Antibodies, Monoclonal; Female; Fractures, Bone; Humans; Osteoporosis | 2018 |
Osteoporosis: Romosozumab to rebuild the foundations of bone strength.
Topics: Alendronate; Antibodies, Monoclonal; Female; Fractures, Bone; Humans; Osteoporosis | 2018 |
A Perfectly Avoidable Crisis.
Topics: Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Middle Aged; Osteopo | 2018 |
Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Drug | 2019 |
Clinical pathologies of bone fracture modelled in zebrafish.
Topics: Alendronate; Animal Fins; Animals; Bony Callus; Diphosphonates; Disease Models, Animal; Fracture Hea | 2019 |
The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Female; Fractures, Bone; Human | 2013 |
Pelvic fractures associated with long-term bisphosphonate therapy - case report.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonate | 2013 |
Pure and hybrid causal effects on variables associated with an incident event.
Topics: Alendronate; Bone Density Conservation Agents; Causality; Computer Simulation; Fracture Healing; Fra | 2013 |
Effects of combined therapy of alendronate and low-intensity pulsed ultrasound on metaphyseal bone repair after osteotomy in the proximal tibia of aged rats.
Topics: Alendronate; Animals; Bone Density; Diphosphonates; Female; Fracture Healing; Fractures, Bone; Osteo | 2014 |
Risedronate improves bone architecture and strength faster than alendronate in ovariectomized rats on a low-calcium diet.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Femal | 2014 |
Alendronate-induced atypical bone fracture: evidence that the drug inhibits osteogenesis.
Topics: Alendronate; Bone Density Conservation Agents; Cell Differentiation; Cell Proliferation; Fractures, | 2014 |
Bone density and bone turnover marker monitoring after discontinuation of alendronate therapy: an evidence-based decision to do less.
Topics: Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Female; Forecasting; Fractures, | 2014 |
Ask the doctor. I've had osteoporosis for several years, and I've been taking alendronate (Fosamax) once a week. I wasn't very good at remembering to take it regularly, so my doctor recently recommended that I start on once-a-year infusions of zoledronic
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Sch | 2014 |
Pathological pelvic fracture following long-term bisphosphonate use in a 63-year-old woman.
Topics: Accidental Falls; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Femal | 2014 |
Duration-dependent effects of clinically relevant oral alendronate doses on cortical bone toughness in beagle dogs.
Topics: Administration, Oral; Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Dogs; Drug Admi | 2015 |
Reversible Deterioration in Hypophosphatasia Caused by Renal Failure With Bisphosphonate Treatment.
Topics: Alendronate; Densitometry; Diphosphonates; DNA Mutational Analysis; Fractures, Bone; Genetic Associa | 2015 |
Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collagen; Dis | 2015 |
Alendronate does not prevent long bone fragility in an inactive rat model.
Topics: Aging; Alendronate; Animals; Bone Density; Female; Fractures, Bone; Immobilization; Osteoporosis; Ov | 2016 |
A rare combination of amniotic constriction band with osteogenesis imperfecta.
Topics: Alendronate; Amniotic Band Syndrome; Bone Density Conservation Agents; Bone Diseases, Metabolic; Chi | 2015 |
Real-Life and RCT Participants: Alendronate Users Versus FITs' Trial Eligibility Criterion.
Topics: Adult; Aged, 80 and over; Alendronate; Body Mass Index; Cohort Studies; Cross-Sectional Studies; Fem | 2016 |
EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
Topics: Adolescent; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling | 2016 |
Use of drugs against osteoporosis in the Baltic countries during 2010-2014.
Topics: Alendronate; Baltic States; Bone Density Conservation Agents; Calcium Channel Blockers; Denosumab; D | 2016 |
Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties.
Topics: Aged; Aged, 80 and over; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents | 2017 |
Review of comparative effectiveness of treatments to prevent fractures.
Topics: Alendronate; Bone Density Conservation Agents; Fractures, Bone; Humans; Osteoporosis; Renal Insuffic | 2008 |
Osteodensitometry in healthy postmenopausal women.
Topics: Absorptiometry, Photon; Age Factors; Aged; Alendronate; Bone Density; Calcium; Clinical Trials as To | 2008 |
Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule | 2009 |
Vitamin D status and response to treatment in post-menopausal osteoporosis.
Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation A | 2009 |
Appropriate intervention through fracture risk assessment.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fractu | 2005 |
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Budgets; Cost-Benefit Analys | 2008 |
DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Diphosphonates; Etidronic Acid; Female; Femur; Fr | 2009 |
Osteoporotic fracture management in India: a survey of orthopaedic surgeons.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; | 2008 |
[Treatment of osteoporosis in the elderly: what is the evidence?].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Ag | 2008 |
Differences in persistence among different weekly oral bisphosphonate medications.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphos | 2009 |
What's the story with Fosamax? Recent reports have women wondering if they should stop taking this widely prescribed osteoporosis drug.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Osteogenesis; | 2008 |
Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Confidence Intervals; Etidronic Acid; Female; F | 2009 |
Atrial fibrillation in fracture patients treated with oral bisphosphonates.
Topics: Aged; Aged, 80 and over; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Case-Co | 2009 |
[Osteoporotic fracture in menopausal women: alendronate reduces the risk].
Topics: Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Hip Fractures; Humans; Middl | 2008 |
Potential of alfacalcidol for reducing increased risk of falls and fractures.
Topics: Accidental Falls; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitriol; Cal | 2009 |
Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone and Bones; Bone Density; Bone Den | 2008 |
Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage.
Topics: Alendronate; Animals; Computer Simulation; Disease Models, Animal; Dogs; Etidronic Acid; Fractures, | 2009 |
Unusual mid-shaft fractures during long-term bisphosphonate therapy.
Topics: Adult; Aged; Alendronate; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidroni | 2010 |
Overcoming resistance to bisphosphonates through the administration of alfacalcidol: results of a 1-year, open follow-up study.
Topics: Absorptiometry, Photon; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agent | 2009 |
A fractured service: will NOGG mend it?
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Fractures, Bone; Hum | 2009 |
Do not use bisphosphonate therapy indefinitely for fracture prevention.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Diphosphonates; Female; Fractures, Bone; Fractur | 2008 |
Corticosteroids: no drug prevention of fractures needed.
Topics: Adrenal Cortex Hormones; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents | 2009 |
Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis?
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Plates; Bone Regeneration; Bony Callus; | 2010 |
[Skeletal biomechanical effectiveness of retinoic acid on induction of osteoporotic rats treated by alendronate and qianggu capsules].
Topics: Alendronate; Animals; Biomechanical Phenomena; Disease Models, Animal; Drugs, Chinese Herbal; Female | 2009 |
Bisphosphonates: atypical fractures. Femur most often involved.
Topics: Alendronate; Diphosphonates; Femoral Fractures; Fractures, Bone; Humans | 2009 |
Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Costs | 2010 |
High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; F | 2010 |
One year of alendronate treatment lowers microstructural stresses associated with trabecular microdamage initiation.
Topics: Alendronate; Animals; Bone and Bones; Calcification, Physiologic; Dogs; Female; Finite Element Analy | 2010 |
Thighbone fractures in women taking bisphosponate drugs.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femo | 2010 |
Skeletal integrity and visceral transplantation.
Topics: Adult; Alendronate; Biomarkers; Bone Density; Female; Fractures, Bone; Humans; Hyperparathyroidism, | 2010 |
Response of postpoliomyelitis patients to bisphosphonate treatment.
Topics: Administration, Oral; Alendronate; Bone Density; Bone Density Conservation Agents; Case-Control Stud | 2010 |
Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective study.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Back Pain; Bone Density Conservation Agents; | 2011 |
Secondary prophylaxis of osteoporotic fractures in an orthogeriatric service.
Topics: Alendronate; Attitude of Health Personnel; Bone Density Conservation Agents; Fractures, Bone; Health | 2011 |
Potency of a combined alfacalcidol-alendronate therapy to reduce the risk of falls and fractures in elderly patients with glucocorticoid-induced osteoporosis.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Alendronate; Back Pain; Bone Density; Bone Density C | 2011 |
RETRACTED: Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes.
Topics: Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density Conservation Agents; Case-Control S | 2011 |
Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2011 |
Alendronate therapy in polyostotic fibrous dysplasia presenting with pathologic fracture.
Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium Carbonate; Cholecal | 2011 |
Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Comparative Effectiveness Research; Diph | 2011 |
[When should bisphosphonate treatment be discontinued?].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female | 2012 |
Bisphosphonate therapy for painless fracture: change of HSAN 1 clinical course with biphosphonate and Vitamin D therapy.
Topics: Alendronate; Cholecalciferol; Diphosphonates; Female; Fractures, Bone; Hereditary Sensory and Autono | 2012 |
Cost-effectiveness of osteoporosis interventions for 'incidental' vertebral fractures.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Computer Simulation; Cost-Benefit Analysis; Dec | 2013 |
When the patient knows best.
Topics: Alendronate; Esophagitis; Female; Fractures, Bone; Hospitalization; Humans; Leg Injuries; Middle Age | 2001 |
[Patients with fractures are in the front line for osteoporosis treatment but how to treat?].
Topics: Alendronate; Bone Density; Calcitonin; Etidronic Acid; Fractures, Bone; Health Services Accessibilit | 2001 |
Skeletal lead release during bone resorption: effect of bisphosphonate treatment in a pilot study.
Topics: Adult; Aged; Alendronate; Bone Remodeling; Bone Resorption; Female; Fractures, Bone; Humans; Isotope | 2002 |
Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats.
Topics: Alendronate; Animals; Estrogens; Female; Fracture Healing; Fractures, Bone; Ovariectomy; Radiography | 2002 |
Hadju-Cheney syndrome: response to therapy with bisphosphonates in two patients.
Topics: Acro-Osteolysis; Adult; Alendronate; Bone Density; Bone Diseases, Developmental; Bone Resorption; Fe | 2003 |
Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.
Topics: Age Factors; Aged; Alendronate; Cohort Studies; Cost-Benefit Analysis; Female; Fractures, Bone; Huma | 2003 |
Efficacy of teriparatide and alendronate on nonvertebral fractures.
Topics: Aged; Alendronate; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Terip | 2003 |
Treatment of children with Osteogenesis imperfecta in Estonia.
Topics: Administration, Oral; Adolescent; Alendronate; Bone Density; Calcitriol; Calcium Channel Agonists; C | 2003 |
[Osteoporosis therapy compared. More solid bones with bisphosphonates].
Topics: Alendronate; Bone Density; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans | 2003 |
Treating osteoporosis with teriparatide: many unknowns?
Topics: Adult; Alendronate; Animals; Bone Density; Canada; Clinical Trials, Phase III as Topic; Drug Costs; | 2003 |
Bone loss after cardiac transplantation.
Topics: Alendronate; Biomarkers; Bone Density; Bone Resorption; Calcitriol; Collagen; Collagen Type I; Fract | 2004 |
[Quality of life of patients suffering from osteoporosis treated with alendronate and salmon calcitonin].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Female; Follo | 2002 |
Decimal point--osteoporosis therapy at the 10-year mark.
Topics: Alendronate; Bone Density; Bone Remodeling; Diphosphonates; Female; Fractures, Bone; Humans; Osteopo | 2004 |
Ten years of alendronate treatment for osteoporosis in postmenopausal women.
Topics: Alendronate; Bone Density; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal | 2004 |
Coming to grips with bone loss.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Remodeling; Carrier Proteins; Estrenes; Est | 2004 |
Osteoporosis management: out of subspecialty practice and into primary care.
Topics: Alendronate; Bone Density; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Primary Healt | 2004 |
Influence of fracture history and bone mineral density testing on the treatment of osteoporosis in two non-academic community centers.
Topics: Adult; Age Factors; Alendronate; Bone Density; Bone Diseases, Metabolic; Calcium, Dietary; Estrogens | 2005 |
Severely suppressed bone turnover: a potential complication of alendronate therapy.
Topics: Aged; Alendronate; Biopsy; Bone Density; Bone Resorption; Female; Fracture Healing; Fractures, Bone; | 2005 |
Effect of treatment with alendronate in osteogenesis imperfecta type I: a case report.
Topics: Adult; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Osteogenesis Imperfecta | 2004 |
Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Disease Models, Animal; Fractures, Bone; Mice; O | 2005 |
Simple computer model for calculating and reporting 5-year osteoporotic fracture risk in postmenopausal women.
Topics: Aged; Alendronate; Bone Density; Computer Simulation; Female; Fractures, Bone; Humans; Middle Aged; | 2005 |
Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women.
Topics: Aged; Aged, 80 and over; Alendronate; Cohort Studies; Cost-Benefit Analysis; Denmark; Female; Fractu | 2005 |
Summaries for patients. Cost-effectiveness of alendronate in postmenopausal women with low bone mass without osteoporosis or previous fracture.
Topics: Aged; Alendronate; Bone Density; Bone Diseases, Metabolic; Cost-Benefit Analysis; Female; Fractures, | 2005 |
Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women.
Topics: Aged; Alendronate; Bone Density; Bone Diseases, Metabolic; Cost-Benefit Analysis; Female; Fractures, | 2005 |
Osteopenia: to treat or not to treat?
Topics: Aged; Alendronate; Bone Diseases, Metabolic; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; | 2005 |
[Calcium gaps in osteoporosis patients close. Blister pack simplifies comedication of calcium and bisphosphonates].
Topics: Alendronate; Calcitonin; Calcium; Clinical Trials as Topic; Cohort Studies; Drug Packaging; Etidroni | 2005 |
Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study.
Topics: Alendronate; Body Height; Body Weight; Bone Density; Bone Density Conservation Agents; Etidronic Aci | 2006 |
Are we treating women with postmenopausal osteoporosis for their low BMD or high fracture risk?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Osteop | 2005 |
The patient's page. Bone health facts.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Dietary Sup | 2005 |
Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Clini | 2005 |
[New therapeutic approaches to osteoporosis].
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Male; Osteoporo | 2006 |
Denosumab in postmenopausal women with low bone mineral density.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density C | 2006 |
[Drug therapy for prevention of falls and fractures].
Topics: Accidental Falls; Alendronate; Bone Density Conservation Agents; Drug Therapy, Combination; Evidence | 2006 |
Case-only analysis of treatment-covariate interactions in clinical trials.
Topics: Alendronate; Analysis of Variance; Bias; Biometry; Clinical Trials as Topic; Cohort Studies; Coronar | 2006 |
Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans | 2006 |
Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone and Bones; Bone Density | 2007 |
Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Fractures, Bone | 2006 |
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Evaluation; Etidronic A | 2007 |
Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; | 2006 |
Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Cos | 2007 |
Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
Topics: Administration, Oral; Alendronate; Bone Density; Bone Density Conservation Agents; Child; Child, Pre | 2007 |
Alendronate and atrial fibrillation.
Topics: Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Female; Fr | 2007 |
Use of alendronate after 5 years of treatment.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Fractures, Bone; Humans; Osteoporosis, | 2007 |
Use of alendronate after 5 years of treatment.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Fractures, Bone; Humans; Osteoporosis, | 2007 |
Use of alendronate after 5 years of treatment.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Fractures, Bone; Humans; Osteoporosis, | 2007 |
Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Cats; | 2007 |
Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diph | 2007 |
Osteoporosis: non-hormonal treatment.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2007 |
Renal function and bisphosphonate safety.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Creatinine; Fe | 2008 |
Bone densitometry and treatment for osteoporosis in older men.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost | 2007 |
Anabolic therapy in glucocorticoid-induced osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Fractures, Bone; Gluco | 2007 |
The cost-effectiveness of alendronate in the management of osteoporosis.
Topics: Alendronate; Bone Density; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; Osteoporosis; Ris | 2008 |
Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Cost-Benefi | 2008 |
Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models.
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; | 2008 |
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.
Topics: Adult; Age Factors; Aged; Alendronate; Body Mass Index; Bone Density Conservation Agents; Etidronic | 2008 |
Effect of inappropriate and continuous therapy with alendronate for ten years on skeletal integrity - observations in two elderly patients.
Topics: Absorptiometry, Photon; Aged, 80 and over; Alendronate; Bone Density; Calcium; Female; Fractures, Bo | 2008 |
The population of health economic models is critical.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysis; Female; Fracture | 2008 |
Considering competing risks . . . Not all black and white.
Topics: Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Decision Making; Diabetes Mellit | 2008 |
Summaries for patients. Drug therapy for osteoporosis.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agent | 2008 |
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Epidemiologic Methods; Etidr | 2008 |
The treatment of postmenopausal osteoporosis.
Topics: Aged; Alendronate; Bone Density; Diphosphonates; Female; Fractures, Bone; Humans; Middle Aged; Osteo | 1995 |
Alendronate in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Diphosphonates; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopa | 1996 |
Alendronate: a new bisphosphonate for the treatment of osteoporosis.
Topics: Alendronate; Bone Density; Diphosphonates; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopa | 1996 |
The Fracture Intervention Trial.
Topics: Alendronate; Bone Density; Costs and Cost Analysis; Female; Fractures, Bone; Hip Fractures; Humans; | 1997 |
Preventing osteoporotic fractures with alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Double-Blind Method; Female; Fractures, Bone; Humans; Middle A | 1997 |
Osteoporosis 2000.
Topics: Alendronate; Calcitonin; Chemoprevention; Cost of Illness; Fractures, Bone; Health Education; Humans | 1996 |
AACE Clinical Practice Guidelines for the Prevention and Treatment of Postmenopausal Osteoporosis.
Topics: Alendronate; Bone Density; Calcitonin; Calcium; Decision Making; Estrogen Replacement Therapy; Femal | 1996 |
Meta-analysis of prevention of nonvertebral fractures by alendronate.
Topics: Alendronate; Female; Fractures, Bone; Humans; Meta-Analysis as Topic; Osteoporosis, Postmenopausal | 1997 |
Meta-analysis of prevention of nonvertebral fractures by alendronate.
Topics: Alendronate; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal | 1997 |
Bone mass, bone loss, and osteoporosis prophylaxis.
Topics: Alendronate; Bone Density; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal | 1998 |
[Fosamax--newest scientific information. Prague, 14 November 1997].
Topics: Alendronate; Bone Density; Fractures, Bone; Humans; Osteoporosis; Postmenopause | 1998 |
[Prevention of osteoporosis-related fractures with alendronate].
Topics: Aged; Alendronate; Diphosphonates; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postm | 1998 |
Tolerability of alendronate. Comparison group taking placebo should have been included.
Topics: Aged; Alendronate; Female; Fractures, Bone; Gastrointestinal Diseases; Humans | 1998 |
[Drug clinics. The drug of the month. Alendronate (Fosamax)].
Topics: Absorption; Alendronate; Biological Availability; Bone and Bones; Bone Density; Fasting; Female; Fra | 1998 |
Alendronate in the treatment of osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Diseases, Metabolic; Calcitonin; Estrogen Replacement Therapy; | 1998 |
Fosamax prevents fractures--for some.
Topics: Alendronate; Bone Density; Female; Fractures, Bone; Humans; Osteoporosis | 1999 |
Alendronic acid: new preparation. Limited efficacy, risk of oesophagitis.
Topics: Alendronate; Clinical Trials as Topic; Diphosphonates; Drug Evaluation; Esophagitis; Female; Fractur | 1998 |
Rebuilding strong bones. Treatment may help prevent millions of fractures.
Topics: Aged; Alendronate; Bone Density; Calcium; Fractures, Bone; Hormone Replacement Therapy; Humans; Long | 1999 |
Alendronate and fracture prevention.
Topics: Alendronate; Bone Density; Female; Fractures, Bone; Humans | 1999 |
Osteoporosis management: physicians' recommendations and womens' compliance following osteoporosis testing.
Topics: Absorptiometry, Photon; Aged; Alendronate; Analysis of Variance; Bone Density; Calcitonin; Calcium; | 1999 |
Alendronate and fracture prevention.
Topics: Alendronate; Bone Density; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Osteoporos | 1999 |
[Number of patients to be treated and number of prevented fractures: clinical efficiency of osteoporosis treatment with diphosphonate alendronate].
Topics: Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Data Interpretation, Statistical; F | 1999 |
[Working title: Will reducing alendronate increase the risk of bone fractures by a decrease in bone density? Benefit from alendronate therapy for women without prior fractures remains uncertain].
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Middle Aged; Os | 1999 |
Early prevention of fracture in osteoporosis: new developments.
Topics: Aged; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmen | 1999 |
How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
Topics: Aged; Alendronate; Bone and Bones; Bone Demineralization, Pathologic; Estrogen Antagonists; Female; | 2000 |
Long-term prevention of bone loss.
Topics: Alendronate; Bone Density; Calcium, Dietary; Cholecalciferol; Dietary Supplements; Female; Fractures | 2000 |
Osteoporosis prevention and treatment.
Topics: Alendronate; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopa | 2000 |
Failure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Calcium Compounds; Comorbidity; Diagnosis, D | 2000 |
Alendronate and nonsteroidal anti-inflammatory drug interaction safety is not established: a reply.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Drug Synergism; Fractures, Bone; Humans; Pepti | 2000 |
Alendronic acid in primary prevention: new indication. No reduction in fracture risk.
Topics: Alendronate; Clinical Trials as Topic; Cost-Benefit Analysis; Esophagitis; Estrogen Replacement Ther | 2000 |
[Research and advertisement. Differences in the effectiveness of alendronate according to risk groups].
Topics: Advertising; Alendronate; Conflict of Interest; Drug Industry; Female; Fractures, Bone; Humans; Rese | 2001 |
Absolute vs. relative numbers in evaluating drug therapy.
Topics: Alendronate; Data Interpretation, Statistical; Etidronic Acid; Female; Fractures, Bone; Humans; Info | 2001 |
A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta.
Topics: Alendronate; Animals; Bone and Bones; Bone Development; Collagen; Disease Models, Animal; Fractures, | 2001 |
Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage.
Topics: Alendronate; Animals; Bone Density; Bone Regeneration; Diphosphonates; Dogs; Etidronic Acid; Female; | 2001 |
Changes in bone remodeling rate influence the degree of mineralization of bone which is a determinant of bone strength: therapeutic implications.
Topics: Adult; Alendronate; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Remodeling; Female; | 2001 |
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
Topics: Aged; Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; | 2002 |